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ABSTRACT
Fragile X syndrome (FXS) is the most common inherited monogenic cause of
intellectual disability. FXS patients exhibit social and language deficits, hyperactivity,
seizures, growth abnormalities, macroorchidism, anxiety, and epilepsy. FXS is caused by
the transcriptional silencing of the fragile X mental retardation gene 1 (Fmr1), resulting in
the loss of the fragile X mental retardation protein (FMRP). FMRP is a selective mRNA
binding protein that plays a role in translation repression. Studies suggest that FMRP
utilizes the miRNA pathway to repress translation of its target mRNAs through an
unknown mechanism. The aim of my thesis is to investigate the mechanism by which
FMRP regulates the translation of specific mRNA targets via the miRNA pathway
using Drosophila melanogaster as a model system. Here, we demonstrate that FMRP
requires the core miRNA-induced silencing complex (miRISC) components, AGO1 and
GW182, to mediate translation repression. Moreover, we show that FMRP itself is
necessary for miRNAs to repress translation of a reporter mRNA, which suggests an interdependent role of FMRP and miRNA in regulating gene silencing. Finally, our findings
elucidate a novel role for GW182 in the maintenance of proper synaptic structure and
morphology at the glutamatergic larval neuromuscular junction (NMJ) in an FMRPdependent manner. We propose that FMRP binds to the 3'UTRs of target mRNAs and
controls translation of target mRNAs in a GW182-dependent manner. Our data improve
current understanding of the normal FMRP function in neurons. We postulate that this
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could assist in the discovery of novel therapeutic targets to treat FXS and related autism
spectrum disorders.
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CHAPTER ONE: INTRODUCTION
1.1 Overview of Fragile X Syndrome (FXS).
Fragile X Syndrome (FXS) is one of the most frequent forms of inherited mental
disability in humans and a widely studied monogenic cause of autism (Ascano et al. 2012;
Khayachi et al. 2018). FXS is an X-linked disorder that affects about 1:4000 males and
1:8000 females worldwide (Crawford et al., 2001; Kashima et al., 2017; Khayachi et al.,
2018; Penagarikano et al., 2007). Patients with FXS exhibit severe intellectual disability,
delayed development, hyperactivity, abnormal facial traits, macrocephaly, attention deficit,
social behavioral problems and male macroorchidism (Boyle and Kaufmann, 2010; Drozd
et al., 2018).
Genetic mapping of disease-causing mutations revealed that FXS results from an
abnormal expansion of trinucleotide ‘CGG’ repeats within the 5' untranslated region (UTR)
of the FMR1 gene (Figure 1; Coffee et al., 1999, 2002; Sutcliffe et al., 1992). These CGG
expansions fall into two classes: premutation and full mutation (Bassell and Warren, 2008;
Hagerman and Hagerman, 2002; Schaeffer et al., 2001). Individuals with relatively modest
expansions (55-200) are considered to have a premutation (Jin et al., 2004a; Todd et al.,
2013). Premutation alleles can cause the increased transcription of FMR1 gene and confer
the risk to develop fragile X-associated tremor/ataxia syndrome (FXTAS) in males and
fragile X-related primary ovarian insufficiency (FXPOI) in females (Chen and Joseph,
2015). In contrast, full mutations are characterized by large expansions (ranging between
1

200- >1000 repeats) (Fu et al., 1991; Li et al., 2008; Schaeffer et al., 2003). This expansion
results in hypermethylation of the promoter region of the FMR1 gene, causing
transcriptional silencing and a loss of the encoded Fragile-X mental retardation protein,
FMRP (Eberhart et al., 1996; Loomis et al., 2013; Pieretti et al., 1991). Subsequent studies
have shown that loss of FMRP alters synaptic structure and function, which contributes to
the profound effects observed on learning, memory and cognitive function (Banerjee et al.,
2018; Bassell and Warren, 2008; Gibson et al., 2008; Grossman et al., 2006; Richter et al.,
2015). Therefore, FMRP deficiency has been well- characterized to directly affect
neurodevelopment in FXS patients.
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Figure 1: A schematic representation of the FMR1 gene and its various allelic forms.
The 5'UTR of the FMR1 gene has a promoter region, polymorphic CGG repeats (pink box),
and the coding region. Based on the number of CGG repeats, the FMR1 gene has three
main classes of alleles. A) Normal alleles: characterized by less than 55 repeats, proper
transcription of FMR1 and translation of FMRP. B) Premutation alleles: Characterized by
55-200 repeats cause increased transcription of FMR1 gene that leads to FXTAS and
FXPOI in individuals. Interesting, this results in increased transcription of a “toxic” mRNA
that accumulates in the nucleus. Thus, overall levels of FMRP are lower than in healthy
individuals. C) Full mutation alleles: Characterized by more than 200 repeats cause an
absence of FMRP transcription and translation and leading to FXS.
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FMRP is a selective mRNA binding protein that is highly expressed in the central
nervous system and testis in mammals (Ashley et al., 1993a; Devys et al., 1993; Hinds et
al., 1993). Neurons in FXS patients are characterized by long, thin immature dendritic
spines (Bagni and Greenough, 2005; Irwin et al., 2001). These structural defects result from
an abnormal synaptic maturation or a failure in the synaptic elimination process (Khayachi
et al., 2018). FMRP plays an important role in the translational regulation of specific
neuronal transcripts, many of which encode proteins essential for synaptic structure and
function (Bassell and Warren, 2008; Bhakar et al., 2012; Edbauer et al., 2010). Previous
studies on the regulation of synaptic translation have shown that mutations in translational
regulators including Smaug, Nanos, and Pumilio also lead to a similar dendritic phenotype
as observed in FXS patients (Gabriela et al., 2013). Taken together, this suggests that the
tight regulation of translation is key to normal synaptic function. Further, this suggests that
loss of translation regulation by FMRP deficiency could lead to these phenotypes in FXS
patients (Bagni and Greenough, 2005) .
Some FXS patients have a normal number of CGG repeats but have missense
mutations in the coding region of FMR1 (Kenny and Ceman, 2016). Two identified
missense mutations are isoleucine to asparagine (I304N) in the RNA binding
ribonucleoprotein K homology domain (KH2), and arginine to glutamine mutation
(R138Q) in a KH-like domain (KH0) (Figure 2; Collins et al., 2010; Feng et al., 1997a;
Kenny and Ceman, 2016; Myrick et al., 2015a). These mutations are linked to defects in
the association of FMRP with polysomes, target mRNAs and interacting proteins (Feng et
al., 1997; Hu et al., 2015; Myrick et al., 2015b; Siomi et al., 1994). Together, these findings
4

support an important relationship between FMRP-mediated translational control and
synaptic dysfunction in FXS (Bassell and Warren, 2008; Ronesi and Huber, 2008).
Currently, there are no effective FDA-approved treatment options in the United
States for FXS patients (Banerjee et al., 2018; Berry-Kravis et al., 2017; Penagarikano et
al., 2007). This is partly due to a significant gap in our understanding of which specific
aspect of neurophysiology is most affected by FMRP deficiency. This suggests that a
deeper understanding of the underlying mechanisms by which FMRP can regulate mRNA
translation is necessary to better understand the pathogenesis in FXS patients and in order
to identify novel therapeutic targets (Banerjee et al., 2018; Belmonte and Bourgeron, 2006;
Darnell et al., 2011; Gross et al., 2012; Hagerman et al., 2012; Krueger and Bear, 2011).
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Figure 2: Domain organization of human FMRP.
The human FMRP protein has three putative mRNA binding domains: KH0 (yellow box),
KH1(pink) KH2 (green), and the RGG box (orange. KH0 contains a nuclear localization
signal (NLS) required for nuclear localization of FMRP. There is also a C-terminal nuclear
export signal (NES) required for its role as a nucleocytoplasmic shuttling protein. Also
shown are the R138Q, G266E, and 1304N point mutations linked to the severe form of
FXS. Indicated above are the amino acid residues.
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1.2 Structure and function of FMRP.
Multiple isoforms of FMRP exist in humans due to alternative splicing but much
remains to be learned about the precise role and functional significance for each of these
variants (Ashley et al., 1993b; Sittler et al., 1996; Verkerk et al., 1993). In mammals, FMRP
belongs to a family of RNA binding proteins that include its autosomal paralogs, the Fragile
X-Related proteins FXR1 and FXR2 (Ceman et al., 1999; Khandjian, 1999; Kirkpatrick et
al., 2001; Siomi et al., 1995; Zhang et al., 1995). FMRP contains three well-defined RNA
binding domains: two KH domains (KH1 and KH2) and an arginine-glycine-glycine
(RGG) box motif (Ashley et al., 1993a; Siomi et al., 1993). FMRP is enriched in the
cytoplasm and binds selectively to about 4% of target mRNAs in the mammalian brain
(Ashley et al., 1993a; Brown et al., 2001; Santos et al., 2014).
Drosophila melanogaster has been widely used as a genetic model system to study
FXS pathology, in part due to the ease of working with fruit flies and conducting genetic
studies in drosophila neurons (Drozd et al., 2018; Weisz et al., 2015). Drosophila expresses
only a single ortholog of FMRP which is called dFMRP (Wan et al., 2000). Sequence
comparison shows that dFMRP has 56% overall amino acid similarity to mammalian
FMRP (Figure 3; Bagni and Oostra, 2013). However, the RNA binding domains are about
75% identical between dFMRP and human FMRP (Chen et al., 2014; Wan et al., 2000) .
Moreover, dFMRP has similar biochemical and neuronal functions compared to
mammalian FMRP (Dockendorff et al., 2002; Inoue et al., 2002; Ishizuka et al., 2002;
Morales et al., 2002; Siomi and Dreyfuss, 1997; Wan et al., 2000; Zhang et al., 2001).
These characteristics make Drosophila a viable system to study FMRP function.
7

In both mammalian and fly neurons, FMRP with its multiple conserved domains
interacts with specific mRNAs to form membrane-less RNA-protein granules (Aschrafi et
al., 2005; Barbee et al., 2006; Bassell, 2011; Mazroui, 2002). In neurons, FMRP is involved
in the transport, targeting and translational regulation of synaptically localized mRNAs in
response to synaptic stimulation (Antar et al., 2004, 2005, 2006; Bassell and Warren, 2008;
Dictenberg et al., 2008; Kiebler and Bassell, 2006; Otero et al., 2002) . Additional details
of the functions of FMRP are discussed in detail below.
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Figure 3: Domain organization of dFMRP.
The dFMRP protein is 56% similar overall to human FMRP with conserved mRNA binding
domains: Shown are the conserved KH0 (yellow), KH1 (pink), KH2 (green), and RGG box
(orange). Also depicted are NES domains (blue) with amino acids on the top. As with
mammalian FMRP, there is an NLS located within the KH0 domain.
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1.2.1 Role of FMRP in regulating neurodevelopment.
Proteins encoded by synaptically localized mRNAs modulate the structure and
strength of synapses, memory formation, and cognitive functions (Bramham and Wells,
2007; Costa-Mattioli et al., 2009; Lin and Holt, 2008; Martin and Zukin, 2006; Steward
and Schuman, 2003; Zukin, 2009). Dysregulation of local protein synthesis and mRNA
transport is closely linked with improper neurodevelopment and synapse maturation
(Bassell, 2011; Gabriela et al., 2013; Xing and Bassell, 2013). FMRP is thought to be
involved in maintaining proper synaptic plasticity by binding to several key neuronal
transcripts and maintaining them in a translationally inactive state in mRNA-containing
ribonucleoprotein (mRNP) granules (Bagni and Greenough, 2005; Ferrari et al., 2007;
Miyashiro et al., 2003; Muddashetty et al., 2007; Todd et al., 2003; Zalfa et al., 2003;
Zukin, 2009).
FMRP is involved in the transport, stability and translation of several neuronal
transcripts (Bagni and Oostra, 2013; Fernández et al., 2013). FMRP transports several
mRNAs, including the Fmr1 mRNA itself, from the cell body towards synapses in an
activity-dependent manner through an association with motor proteins including kinesin
(Fernández et al., 2013; Ferrari et al., 2007). For example, the loss of FMRP impairs the
localization of several important mRNA targets such as MAP1B and the PSD-95associated protein 4 (Sapap4) mRNA to synapses (Dictenberg et al., 2008; Kao et al.,
2010). Furthermore, FMRP can modulate the stability of some mRNAs by preventing or
promoting mRNA decay (Fernández et al., 2013; Zalfa et al., 2010; Zhang et al., 2007).
For example, previous studies have shown that the association of hippocampal FMRP can
10

protect PSD-95 transcript from decay (Zalfa et al., 2010). In contrast, it can promote the
decay of nuclear RNA export factor 1 (NXF1) transcript in mouse neuroblastoma (N2a)
cells (Zhang et al., 2007). Together, this suggests that FMRP’s interaction with specific
transcripts regulates their stability and localization in a transcript-dependent manner.
FMRP plays an important role in repressing the translation of a subset of mRNAs.
Studies in cells derived from FXS patients as well as mice and flies lacking FMRP show
an increased rate of translation for mRNAs targeted by FMRP (Bolduc et al., 2008; Brown
et al., 2001; Dolen et al., 2007). These data support a role for FMRP as a translation
repressor. Based in part on these data, it is hypothesized that translation dysregulation of
FMRP associated mRNAs is the major contributor to FXS pathology (Bagni and Oostra,
2013; Fernández et al., 2013; Richter et al., 2015). In the absence of FMRP, key target
mRNAs are excessively translated in dendritic spines leading to defects in synaptic
morphology (Bagni and Greenough, 2005; Cruz-Martín et al., 2012; Darnell and Klann,
2013; Grossman et al., 2006; Mientjes et al., 2006; Nimchinsky et al., 2001; The Fragile X
Consortium, 1994; Zhang et al., 2001).
In mammalian neurons, FMRP activity is regulated by metabotropic glutamate
receptor (mGluR) stimulation (Antar et al., 2004; Bear et al., 2004; Dictenberg et al., 2008;
Weiler et al., 1997). Activation of mGluR induces the rapid dephosphorylation of FMRP
followed by ubiquitination and subsequent proteasome-mediated degradation (Hou et al.,
2006; Nalavadi et al., 2012). As a result, specific FMRP-bound mRNAs are released from
RNP granules and translated to make proteins (Aschrafi et al., 2005; Bear et al., 2004;
Muddashetty et al., 2011). Conversely, phosphorylation of FMRP inhibits the translation
11

of its associated mRNA (Narayanan et al., 2007; Niere et al., 2012). Interestingly, recent
studies suggest that the activation of mGLuR can also lead to the reversible sumoylation
of FMRP, suggesting that mGLuR activation can regulate FMRP’s function through
different mechanisms (Khayachi et al., 2018).
Many studies have focused on identifying the mRNAs whose translation is
regulated by FMRP in order to understand the neuropathology of FXS (Banerjee et al.,
2018; Darnell and Klann, 2013; Richter et al., 2015). Several approaches have been used
to identify FMRP associated mRNAs in neuronal mRNA granules (Brown et al., 2001;
Darnell et al., 2011; El Fatimy et al., 2016). Isolation and purification of FMRP-containing
neuronal granules from mouse brain homogenates has led to the identification of several
associated

transcripts

(El

Fatimy

et

al.,

2016).

Additionally,

crosslinking-

immunoprecipitation combined with high-throughput sequencing (HITS-CLIP) has been
used to identify FMRP-associated target mRNAs (Darnell et al., 2011).

Finally,

photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PARCLIP) approach was utilized to isolate FMRP bound target mRNAs and to identify binding
sites (Ascano et al., 2012). Collectively, these studies have demonstrated that FMRPassociated target mRNAs that encode for key proteins involved in the control of synaptic
structure and function. Some notable examples of these mRNAs include the microtubuleassociated protein 1b (MAP1B), Down syndrome cell adhesion molecule (DSCAM),
Postsynaptic density protein 95 (PSD-95), FMRP, Ataxin, Human antigen R (HuR),
Calcium/Calmodulin-dependent protein kinase II (CaMKII), Amyloid precursor protein
(APP), the Activity-regulated cytoskeleton-associated protein (ARC), Zinc-finger
12

CysCysCysHis [CCCH]-type 14 (ZC3H14), Ras-related C3 botulinum toxin substrate 1
(Rac1) and Staufen2 (Bienkowski et al., 2017; Brown et al., 2001; Darnell et al., 2011;
Davis and Broadie, 2017; Elvira et al., 2006; El Fatimy et al., 2016; Kanai et al., 2004;
Muddashetty et al., 2007; Sudhakaran et al., 2014; Suhl et al., 2015; Zalfa et al., 2003;
Zhang et al., 2015). FMRP granules are also enriched in mRNAs which encode for
molecular motor proteins (Dync1h1, Myo18a, Myh10, Myo5a) and several members of the
spectrin and ankyrin families, which are essential for synaptic stability and maintenance
(Darnell et al., 2011; El Fatimy et al., 2016; Lindsay and Mccaffrey, 2014). Targets of
dFMRP have also been identified in Drosophila neurons, including Futsch (the fly
orthologue of MAP1B), Dscam (the fly orthologue of DSCAM), chickadee (the fly
orthologue of Profilin), Rac1 (the fly ortholog of Rho GTPase RAC1) and pickpocket1 (the
fly ortholog of PPK1) (Lee, 2003; Reeve et al., 2005; Sterne et al., 2015; Xu et al., 2004;
Zhang et al., 2001). These studies provide an extensive list of mRNAs whose activity is
regulated by FMRP, and mis-regulation of which may contribute to aberrant dendritic spine
development in Fragile X patients (El Fatimy et al., 2016).
1.2.2 Function of RNA binding domains of FMRP.
FMRP has multiple conserved RNA binding domains that allow it to bind to and
regulate the translation of several mRNAs (Ashley et al., 1993a; Gareau et al., 2013a;
Siomi et al., 1996). Previous studies have demonstrated that essential functions of FMRP
rely on functional KH domains, as missense mutations within these domains can cause a
severe form of FXS. These mutations (G266E within KH1), I304N in KH2 and R138Q in
KH0) disrupt the association of FMRP with target mRNA and polyribosomes (Figure 2;
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De Boulle et al., 1993; Feng et al., 1997a; Hu et al., 2015; Myrick et al., 2014, 2015b,
2015a). However, the precise role of these KH domains in mediating the interaction of
FMRP with target mRNAs is not clear. Darnell et al demonstrated that KH2 domain binds
to a double stem-loop structure in RNAs known as “kissing complex” or “loop-loop
pseudo-knot” (Darnell et al., 2005; Kenny and Ceman, 2016). The authors showed that
RNAs with this structure could compete FMRP off polyribosomes, suggesting that FMRP
strongly binds to RNAs containing this secondary structure (Darnell et al., 2005).
However, no structure of this type has been reported in any known endogenous target
mRNAs (Santoro et al., 2012). The identity of specific structures in mRNA targets bound
by KH1 and KH0 domains is not known (Kenny and Ceman, 2016). Thus, the precise role
and function of KH domains in binding target mRNAs needs to be studied in detail.
FMRP also possesses a well-characterized RGG box motif, which selectively binds
to G-rich secondary structures known as G-quadruplexes (GQs) (Blackwell et al., 2010;
Darnell et al., 2001, 2004; Dolzhanskaya, 2006; Menon and Mihailescu, 2007; Phan et al.,
2011; RAMOS, 2003; Schaeffer et al., 2001). G-quadraplexes are formed by guanine
tetrads held together by Hoogsteen base-pairing and stabilized by monocations (BliceBaum and Mihailescu, 2014; Joachimi et al., 2009; Santoro et al.; Schaeffer et al., 2001;
Williamson et al., 1989). Studies show FMRP binds to several target mRNAs including
MAP1B which are capable of folding into distinct G-quadruplex structures (Darnell et al.,
2001; Schaeffer et al., 2001). This suggests that FMRP can regulate the activity of specific
mRNAs that can fold into G-quadruplex substructures.
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Recent studies also have indicated that low complexity domains (LCDs) within the
conserved RGG motif can modulate the flexible interactions of FMRP with several mRNA
ligands and proteins (Kenny and Ceman, 2016; Ozdilek et al., 2017). These domains are
unstructured and disordered in solution, become structured when bound to a target mRNA,
and are proposed to drive RNP granule formation (Coletta et al., 2010; Kenny and Ceman,
2016). However, it is not clear whether these domains co-operate with other domains of
FMRP to mediate its activity (Davis and Broadie, 2017).
1.2.3 FMRP binds to distinct mRNA sequence and structural elements.
The RNA binding domains of FMRP recognize a variety of specific sequence and
structural motifs in target mRNAs (Ashley et al., 1993a; O’Donnell and Warren, 2002;
Siomi et al., 1993). Recent studies using PAR-CLIP indicate that the KH2 and KH1
domains of FMRP preferentially bind to ACUK, WGGA and GAC sequences in target
mRNAs (in which K=G or U and W= A or U) (Ascano et al., 2012; Ray et al., 2013; Suhl
et al., 2014b, 2014a). However, the frequency of these sequences to be present in all human
mRNAs is very high (1 in 128 nucleotides) (Chen et al., 2014). Therefore, it is unknown
how these sequences can provide FMRP the specificity required to bind to its target
mRNAs (Chen et al., 2014). G-quadruplex structures are found in several (but not all)
FMRP-associated targets including the Fmr1, MAP1b, and Sema3F mRNAs (Didiot et al.,
2008; Menon and Mihailescu, 2007; Menon et al., 2008; Santoro et al.,2012; Schaeffer et
al., 2001). However, an analysis of FMRP associated neuronal mRNAs in mice by HITSCLIP did not show an enrichment for G-rich quadruplexes or pseudoknot forming
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sequences (Darnell et al., 2011; Kenny and Ceman, 2016). Therefore, specific RNA
elements that recruit FMRP to target mRNAs are not well understood.
FMRP has been shown to bind to other structural motifs in specific target mRNAs.
For example, FMRP binds to a unique structural motif composed of three independent
stem-loops in the superoxide Dismutase 1 (Sod1) mRNA through the RGG box domain
(Anderson et al., 2016). This motif termed as ‘Sod1 mRNA Stem Loops Interacting with
FMRP’ (SoSLIP) competes with the GQs for binding to the RGG box (Bechara et al., 2009;
Santoro et al., 2012). Surprisingly, these motifs are structurally modified upon interaction
with FMRP and promote the translation of Sod1, in contrast to FMRP’s canonical role as
a translation repressor (Bechara et al., 2009). Other RNA secondary motifs have also been
identified in FMRP targets, including U-rich sequences with 5-23 bases of U-rich pentamer
repeats in some FMRP target mRNAs (Chen et al., 2003; Dolzhanskaya et al., 2003;
Fähling et al., 2009). The U-rich motifs need further characterization as not much is known
about the role of these motifs or the specific domains in FMRP that mediate this interaction
(Santoro et al., 2012).
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1.3 FMRP acts as a translation repressor through different mechanisms.
FMRP is characterized as a protein that regulates the translation of several mRNAs
in mammalian cells. An early study identified FMRP to be associated with the 60S
ribosomal subunit (Siomi et al., 1996). However, the functional consequences of that
association were not known. Laggerbauer et al. provided the first evidence for a function
of FMRP in translation regulation (Laggerbauer et al., 2001). The authors incubated
recombinant FMRP with in vitro transcribed mRNAs encoding for the survival of motor
neuron (SMN) protein, FMRP or the luciferase protein in rabbit reticulocyte lysate assays.
In this system, FMRP strongly inhibited the translation of all these mRNAs in a sequenceindependent manner. Moreover, Xenopus oocytes injected with the FMRP-mRNA
complexes showed identical results (Laggerbauer et al., 2001). Immortal cells from Fmr1
KO mice provided the first in vivo evidence for FMRP function as a translation repressor
(Mazroui, 2002). Fmr1 KO cells were co-transfected with human FMRP and reporter genes
encoding for FXR1P and the sine oculis homeobox homolog transcription factor (SIX3)
(Mazroui, 2002). The transfection of human FMRP led to a reduction in the translation of
reporter genes, suggesting FMRP to be a negative regulator of translation.
Consistent with the role of FMRP as a translation repressor, in vivo assays in Fmr1
KO mice exhibited an increase in the expression of FMRP-target proteins including
MAP1B, Arc and CamKII (Santoro et al.; Zalfa et al., 2003). dFmr1 null flies also showed
an increase in the expression of the MAP1B ortholog, futsch (Zhang et al., 2001).
Moreover, subcellular fractionation of synaptoneurosomes from Fmr1 KO mice show
elevated expression levels for other FMRP target proteins (Zalfa et al., 2003). Together,
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these results highlight the ability of FMRP to repress the translation of several mRNAs in
both mammalian cells and in Drosophila neurons.
Several in vitro studies suggested that direct interaction of FMRP with its target
mRNA is critical for translation repression (Li et al., 2001). The authors removed the
3'UTR from the myelin basic protein mRNA (MBP), a known target of FMRP regulation
in mammalian oligodendrocytes, and observed an inability of FMRP to repress its
translation (Li et al., 2001; Wang et al., 2004; Zalfa et al., 2010). In contrast, FMRP
repressed the translation of the full length MBP transcript (Li et al., 2001). This suggests
that the association of FMRP with its target regulates its ability to repress translation.
In addition to interacting with polyribosomes, FMRP also localizes to RNP
granules knows as P-bodies and stress granules, which are high-order complexes that
contain repressed mRNAs (Barbee et al., 2006; Mazroui, 2002; Santoro et al., 2012).
FMRP is hypothesized to control the translation of mRNAs in part by promoting their
movement between these “storage” granules and polysomes (Aschrafi et al., 2005; Bassell
and Warren, 2008). However, the mechanism behind this process remains unknown.
FMRP is suggested to be an effector of translational repression through several
different mechanisms (Ascano et al., 2012; Brown et al., 2001; Chen et al., 2014; Darnell
et al., 2001, 2005; Jin et al., 2004b; Kenny and Ceman, 2016; Stefani, 2004; Zalfa et al.,
2003). However, these mechanisms by which FMRP regulates translation of neuron targets
remain poorly understood (Bagni, 2008; Chen et al., 2014; Costa-Mattioli et al., 2009;
Iacoangeli et al., 2008a; Kenny and Ceman, 2016). FMRP can repress the translation of
target mRNAs at both initiation and elongation stages (Bhakar et al., 2012; Ceman et al.,
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2003; Santoro et al., 2012). FMRP also regulates mRNA translation via the miRNA
pathway in P-bodies (Barbee et al., 2006; Eulalio et al., 2007a; Parker and Sheth, 2007). It
is important to note that these mechanisms are not mutually exclusive. It is likely that the
repression of FMRP targets by FMRP binding is mRNA specific.
1.3.1 Evidence that FMRP stalls translation at the elongation stage.
Previous studies suggest that FMRP causes ribosomes to stall during the elongation
stage of translation (Figure 4). In-vivo CLIP studies of FMRP demonstrate that it can
directly bind to the coding regions of some target mRNAs (Stefani, 2004). Subsequent
studies by Darnell and colleagues demonstrated that FMRP co-sediments with
polyribosomes and confers resistance to puromycin, which releases elongating ribosomes
(Darnell et al., 2011; Harigaya and Parker, 2014). These results indicate that by binding to
coding regions of mRNA, FMRP could either block puromycin action or could impede
ribosome movement to slow translation elongation. Interestingly, after puromycin
treatment, target mRNAs of FMRP were deeper in the polysome gradient compared to nontargets (Darnell et al., 2011; Harigaya and Parker, 2014). These results suggest FMRP
causes increased retention of ribosomes on target mRNA. The authors further characterized
FMRP-stalled complex with electron microscopy and demonstrate target mRNAs to be
complexed with multiple ribosomes (Darnell et al., 2011). Ribosomal run-off assays on
these transcripts also demonstrate that FMRP is associated with stalled ribosomes on these
transcripts (Ceman et al., 2003). Phosphorylation of FMRP at serine residues correlates
with its association with stalled polyribosomes, and dephosphorylated FMRP associates
with actively translating polyribosomes (Ceman et al., 2003). These results suggest that the
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molecular mechanism controlling FMRP phosphorylation may thereby regulate translation
elongation of FMRP targeted mRNAs.
Recent cryo-electron microscopic studies in Drosophila suggest that FMRP stalls
ribosome movement on mRNAs to repress their translation (Chen et al., 2014; Harigaya
and Parker, 2014). The authors showed that FMRP directly binds to the L5 protein of 80S
subunit of the ribosome, blocking the access of tRNAs and essential translation elongation
factors to inhibit translation (Chen et al., 2014). According to Chen et al., FMRP binds to
specific structural elements in target mRNA, which leads to the KH2 domain of FMRP
interacting with the 80S subunit of the ribosome (Chen et al., 2014; Harigaya and Parker,
2014). This interaction causes a steric conflicts with the tRNA at the P-site, leading to
ribosomal stalling (Chen et al., 2014). These results also explain why FMRP-bound
mRNAs are resistant to puromycin treatment, since FMRP’s interaction with the 80S
subunit will block access of puromycin to the ribosome.
Recent studies directly compared the movement of ribosomes along mRNAs in
brain lysates from wild-type and Fmr1 KO mice (Richter et al., 2015; Udagawa et al.,
2013). These lysates were supplemented with hippuristanol, a drug that blocks new
translation initiation, allowing ribosomes already associated with transcripts to runoff the
transcript after completing translation (Bordeleau et al., 2006; Richter et al., 2015;
Udagawa et al., 2013).

The authors found that the rate of radioactive amino acid

incorporation was higher in Fmr1 KO lysates compared to wild-type lysates. Given that
new translation initiation was blocked in these experiments, these results strongly suggest
that FMRP stalls ribosomes on target mRNAs and blocks translation elongation.
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Figure 4: FMRP regulates mRNA translation at the elongation stage.
FMRP can stall the progression of ribosomes along the target mRNA. Electron microscopy
shows FMRP to be in a complex with polyribosomes. Recent cryo-EM studies demonstrate
that dFMRP can directly bind to the 80S ribosome through KH2 domains and interfere
with the binding of essential elongation factors to the ribosome. Post-transcriptional
modification of FMRP such as phosphorylation at serine residues and methylation on
arginine residues can modulate the association of FMRP with ribosomes.
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1.3.2 Evidence that FMRP stalls translation at the initiation stage.
While a significant amount of research points to a role of FMRP in regulating
translation at elongation stage, some data suggests that FMRP blocks the translation of
specific mRNAs at the initiation stage. Specifically, it was shown that FMRP can block
translation initiation by modulating the interaction between the cytoplasmic FMRPinteraction protein (CYFIP1) and eukaryotic initiation factor eIF4E which binds to the
m7G cap and initiates translation (Figure 5; Napoli et al., 2008; Richter et al., 2015;
Schenck et al., 2001). Bulk cap-dependent translation requires the formation of the eIF4AeIF4G-eIF4E (eIF4F) complex in association with the 5’ m7G cap structure (Richter and
Sonenberg, 2005). eIF4E-binding proteins (4E-BPs) regulate the formation of eIF4E
complex by interfering with eIF4E-eIF4G interaction (Banko et al., 2007; Klann and
Richter, 2007; Marcotrigiano et al., 1999; Richter and Sonenberg, 2005), and
phosphorylation of 4E-BPs results in their dissociation from eIF4E and initiation of
translation (Gingras et al., 2001). FMRP interacts biochemically with CYFIP1, a protein
which has a non-canonical eIF4E-binding protein (4E-BP) domain (Marcotrigiano et al.,
1999). Another binding partner of FMRP, the noncoding brain cytoplasmic RNA 1 (BC1),
helps to facilitate the interaction between FMRP and the CYFIP-eIF4E complex in the
mammalian brain (Napoli et al., 2008; Zalfa et al., 2003, 2005).
FMRP-CYFIP1-eIF4E is transported as a translationally inactive complex in
dendrites stabilized by target mRNAs and responds to synaptic stimulation induced by
either brain-derived neurotrophic factor (BDNF) or group 1 mGluR signaling (DeRubeis
et al., 2013; Napoli et al., 2008). Evidence suggests that local synaptic stimulation results
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in the release of FMRP-CYFIP1 from eIF4E to rapidly alleviate translation repression
(DeRubeis et al., 2013; Napoli et al., 2008; Richter et al., 2015). Consistent with these
results, genetic loss of CYFIP1 in the brain results in an increase in the expression of known
FMRP targets including MAP1B, APP, CaMKII (Bagni and Greenough, 2005; Hou et al.,
2006; Napoli et al., 2008; Westmark and Malter, 2007).
The in vivo significance of the FMRP-BC1-CYFIP interactions, however, has been
challenged (Iacoangeli et al., 2008a, 2008b; Stefani, 2004; Wang et al., 2005). In one
specific study, the authors were unable to detect specific interactions between FMRP and
BC1 mRNA in vitro (Iacoangeli et al., 2008b). Moreover, competitor tRNA abolished the
association between FMRP and BC1 mRNA in mobility shift assays, suggesting that the
binding of FMRP to BC1 may be non-specific (Iacoangeli et al., 2008b; Wang et al., 2005).
Therefore, the model of FMRP-mediated interaction between CYFIP1 and eIF4E and its
role in blocking translation initiation is contested.
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Figure 5: FMRP regulates mRNA translation at the initiation stage.
FMRP has been shown by some to recruit CYFIP1 (orange) and sequester the general
translation initiation factor eIF4E (green) from binding to eIF4G (light green). The
inability to form the pre-initiation complex leads to translation repression. BC1 mRNA
increases the affinity of FMRP-CYFIP1 interaction in vitro. Studies propose that in
response to mGLuR activation, the CYFIP1-FMRP complex gets released from eIF4E for
the local translation at the synapses. This model of action is highly contested.
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1.4 miRNA biogenesis and miRISC assembly.
FMRP can also regulate the translation of target mRNAs through its interaction
with specific miRNAs and conserved components of the RNA-induced silencing complex
(RISC) (Figure 6; Fabian and Sonenberg, 2012). Recent studies suggest that FMRP
cooperates with miRNAs to modulate synaptic structure and function (Loffreda et al.,
2015). Before addressing the details of how FMRP interacts with miRNAs and miRISC,
an overview of the regulation of miRNA biogenesis and function is summarized below.
miRNAs are small ~22 nucleotide non-coding mRNAs with an important role in
regulating gene expression by binding to complementary mRNAs and regulating
translation (Baek et al., 2008; Bartel, 2009; Eulalio et al., 2008a; Fabian et al., 2010; Ha
and Kim, 2014; Krol et al., 2010; Lim et al., 2005; Selbach et al., 2008). Published evidence
indicates a role for miRNAs in nearly every biological process ranging from development
to the regulation of the cell cycle and synaptic plasticity (Ambros, 2011; Bushati and
Cohen, 2007; Eulalio et al., 2008a; Kim et al., 2009; McNeill and Van Vactor, 2012; Nesler
et al., 2013; Shenoy and Blelloch, 2014). miRNA biogenesis and function are tightly
regulated, and dysregulation of their expression or function is linked to human diseases
ranging from cancer to neurodevelopment disorders (Chang and Mendell, 2007; Garzon et
al., 2009; McNeill and Van Vactor, 2012; Saugstad, 2010).
miRNA genes are transcribed by RNA polymerase II (Pol II) to form the long
primary miRNA (pri-miRNA) (Figure 7; Filipowicz et al., 2008a; Ha and Kim, 2014; Kim,
2005; Lee et al., 2004a). Following transcription, the pri-miRNA undergoes several steps
of processing (Denli et al., 2004; Ha and Kim, 2014). The pri-miRNA folds into a dsRNA
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hairpin structure with the embedded miRNA sequences and undergoes cleavage by the
microprocessor complex to form precursor miRNAs (pre-miRNA) (Kim et al., 2009; Lee
et al., 2002). The microprocessor complex is composed of dsRNA binding proteins with
endonucleolytic activity: DROSHA and DGCR8 (Pasha in flies)(Du, 2005; Gregory et al.,
2004; Han et al., 2004, 2006; Kim et al., 2009; Landthaler et al., 2004). The pre-miRNA is
exported from into the cytoplasm by Exportin 5 (XPO5) in a RAN-GTP dependent manner
(Bohnsack et al., 2004; Kim, 2004; Lund et al., 2004). Upon export, the pre-miRNA is
further cleaved by Dicer to produce a miRNA duplex of approximately 22 nucleotides
(Bernstein et al., 2001; Grishok et al., 2001; Hutvágner et al., 2001; Ketting et al., 2001;
Knight and Bass, 2001). Like DROSHA, Dicer also belongs to an RNAase endonuclease
family and cleaves dsRNAs (Ma et al., 2004; Song et al., 2003; Zhang et al., 2004). Dicer
acts as a molecular ruler and cuts miRNAs at specific cleavage sites with a fixed distance
of about 22-25 nucleotides from either 3' or 5' end (Coffee et al., 2002; Macrae et al., 2006;
MacRae et al., 2007; Vermeulen et al., 2005; Zhang et al., 2002, 2004). Although mammals
have a single Dicer gene, Drosophila expresses two Dicer paralogs (Ha and Kim, 2014;
Kim et al., 2009). Dicer 1 is required for miRNA biogenesis whereas Dicer 2 is involved
in short interfering (siRNA) processing (Lee et al., 2004b). Several RNA binding proteins
(RBPs) modulate the activity of Dicer for efficient processing of most miRNAs
(Chendrimada et al., 2005; Förstemann et al., 2005; Fukunaga et al., 2012; Lee and
Doudna, 2012; Lee et al., 2013; Saito et al., 2005; Trabucchi et al., 2009). In Drosophila,
Dicer1 associates with Loquacious (Loqs) for efficient pre-miRNA processing (Kim et al.,
2009), whereas in humans, Dicer interacts with TAR RNA binding protein (TRBP) and
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Protein activator of the interferon-induced protein kinase (PACT) protein for formation of
the miRISC complex (Ha and Kim, 2014; Kim et al., 2009).
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Figure 6: FMRP regulates mRNA translation through the interaction with the
miRISC components.
Genetic and biochemical studies show that FMRP associates directly with miRNAs, Dicer,
and AGO1. AGO1 is a core component of the miRNA-containing RISC complex
(miRISC). FMRP can recruit the miRISC complex to facilitate the recognition of target
mRNAs and regulate the translation of a target mRNA using miRNAs. The FMRP-miRISC
complex can repress translation at either the initiation or at the elongation stage. The
mechanisms regulating the interaction between FMRP and the RISC remain unclear.
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Figure 7: A schematic of miRNA biogenesis and their assembly into miRISC
complex.
miRNA genes are transcribed by RNA polymerase II to generate the pri-miRNA. The
nuclear endonuclease DROSHA and DGCR8 process the pri-miRNA to form the premiRNA hairpin structure. Then, XPO5 recognizes the pre-miRNA and exports it to the
cytoplasm for further processing by Dicer. Dicer catalyzes the formation of the pre-miRNA
to generate miRNA duplex. One strand of the duplex, known as the guide strand, is
preferentially loaded onto the AGO proteins to form the miRISC complex. The miRISC
complex binds to miRNA binding sites, primarily in the 3'UTR of the target mRNA to
mediate translation repression or decay. The nucleotides at the 5'end of the miRNA known
as the miRNA seed are crucial for the recognition of the target mRNA.
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1.4.1 miRNA loading and RNA induced silencing complex formation.
Once the mature miRNA duplex is generated following several processing steps,
the duplexed RNA is loaded onto the Argonaute (AGO) protein (Figure 7; Elkayam et al.,
2012; Gregory et al., 2005; MacRae et al., 2008; Maniataki and Mourelatos, 2005;
Nakanishi et al., 2012; Schirle and MacRae, 2012). Loading of the miRNA duplex is
followed by a subsequent unwinding of the strands. The non-associated strand, called the
“passenger strand”, is released and degraded, whereas the active strand, called the “guide
strand” is retained to complete the formation of the miRNA-containing RISC (Diederichs
and Haber, 2007; Ha and Kim, 2014; Kawamata and Tomari, 2010). The guide strand is
selected on the basis of the relative thermodynamic stability of the 5' and 3' end of the small
RNA duplex (Khvorova et al., 2003; Schwarz et al., 2003).
Mammals express four AGO paralogs (AGO1-4) which are capable of inducing
translation repression or decay of target mRNAs to varying degrees utilizing either the
miRNA or the siRNA pathways (Ha and Kim, 2014; Huntzinger and Izaurralde, 2011;
Ipsaro and Joshua-Tor, 2015; Yoda et al., 2010). In contrast, Drosophila expresses two
paralogs of the AGO proteins (dAGO1 and dAGO2) (Förstemann et al., 2007; Okamura et
al., 2004; Tomari et al., 2007). dAGO1 is utilized by the miRNA pathway and dAGO2 is
utilized by the siRNA pathway (Czech et al., 2009; Kawamata et al., 2009).
Thermodynamic stability of base-pairing between the miRNA and complementary
sequences generally located in the 3'UTR of target mRNA determines the ability of miRNA
to repress translation of target mRNA (Clarke et al., 2012). The nucleotides at positions 28 at the 5' end of the miRNA, known as seed region, are crucial for miRNA target
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recognition (Ameres and Zamore, 2013; Bartel, 2009; Brennecke et al., 2005; Doench and
Sharp, 2004; Grimson et al., 2007; Pasquinelli, 2012). Following miRNA binding, the
regulation of target mRNAs is facilitated by another core protein component of the
miRISC, the trinucleotide repeat containing protein (TNRC; also known as GW182;
Eulalio et al., 2008b, 2009; Fabian and Sonenberg, 2012; Huntzinger and Izaurralde, 2011;
Pfaff and Meister, 2013). The primary function of GW182 is to acts as a scaffold for other
accessory proteins that mediate either translation repression or mRNA degradation (Braun
et al., 2011, 2013; Chekulaeva et al., 2011; Fabian and Sonenberg, 2012; Fabian et al.,
2012; Huntzinger et al., 2010, 2013; Zekri et al., 2009). How the bound miRNA regulates
translation of the target mRNA is described in detail below.
1.4.2 Mechanisms of miRNA-mediated gene silencing.
miRNAs have been shown to target mRNAs for translational repression via four
distinct mechanisms: translation initiation, translation elongation, premature termination
(ribosome drop off) and co-translational protein degradation (Chendrimada et al., 2007;
Eulalio et al., 2008a; Hu et al., 2010; Humphreys et al., 2005; Kiriakidou et al., 2007;
Maroney et al., 2006; Nottrott et al., 2006; Petersen et al., 2006; Pillai et al., 2005;
Seggerson et al., 2002; Tat et al., 2016). miRNAs can also directly target mRNAs for
degradation (Figure 8; Bagga et al., 2005; Braun et al., 2011; Chekulaeva et al., 2011;
Eulalio et al., 2007b; Fabian et al., 2012; Rehwinkel et al., 2005; Wu et al., 2006). mRNA
degradation is initiated by a gradual shortening of the poly (A) tail by components of the
deadenylase complexes, CCR4-NOT1 and PAN2-PAN3 (Antic et al., 2015; Decker and
Parker, 2012; Houseley and Tollervey, 2009; Parker and Song, 2004). In eukaryotes, the
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poly (A) tail is initially shortened by the PAN2-PAN2 complex, followed by rapid
deadenylation by the CCR4-NOT complex (Wahle and Winkler, 2013; Yamashita et al.,
2005). Following deadenylation, mRNAs can either be degraded by the exosome in a 3'-5'
manner or undergo decapping by the DCP1-DCP2 complex followed by 5'-3' decay by the
XRN1 exonuclease (Decker and Parker, 2012; Meyer et al., 2004).
There is a lack of clear understanding of what factors determine whether a specific
mRNA-regulated mRNA will undergo translation repression or degradation (Eulalio et al.,
2008a). Thus, whether or not miRNAs elicit mRNA degradation is likely to be strongly
dependent upon specific features of the miRNA-binding site, miRISC factors, specific
accessory proteins associated with the miRISC, target mRNA and various additional
interacting RBPs (Eulalio et al., 2007b, 2008a; Grimson et al., 2007). The evidence
supporting known mechanisms of miRNA-mediated translation repression at both the
initiation and elongation stages are outlined below.
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Figure 8: Mechanisms of miRNA mediated target gene silencing.
miRNAs (red) can either inhibit translation of target mRNAs or facilitate their
deadenylation followed by subsequent decapping, and decay. These mechanisms require
core components of the miRISC complex, AGO1 (orange), and GW182 proteins (green).
miRNAs can repress the translation of target mRNAs by blocking translation initiation,
elongation or by premature termination of ribosomes. Alternatively, GW182 can recruit
the components of the deadenylase complex (CAF1, CCR4 and the NOT proteins) to
facilitate deadenylation of the poly (A) tail. Following deadenylation, the Dcp1-Dcp2
complex removes the m7G cap to facilitate 5’ to 3’ exonucleolytic decay. Repressed
mRNAs can move to P-bodies for either storage or degradation. Deadenylation as well as
the displacement of poly(A)-binding protein (PABP) through GW182 and CCR4–NOT
also contribute to the overall miRNA-mediated translational repression.
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1.4.2.1 Translation repression by miRNAs at the initiation stage.
Several studies suggest that miRNAs inhibit translation of target mRNAs at the
initiation stage ( Figure 9; Eulalio et al., 2008a). Pillai et al demonstrated that miRNAs and
target mRNAs do not co-sediment with the polysomal fractions in sucrose gradients, but
rather with the free mRNP pool in mammalian cells (Humphreys et al., 2005; Pillai et al.,
2005). These results are indicative of a defect in translational initiation due to an impaired
ribosome recruitment (Ding and Großhans, 2009; Fabian and Sonenberg, 2012). This work,
coupled with several other studies, showed that mRNAs lacking the m7G cap can bypass
miRNA mediated repression. This indicates that miRNAs can target the m7G capdependent translation and inhibit translation at the initiation stage (Filipowicz et al., 2008;
Pillai et al., 2005; Wu and Belasco, 2008). Moreover, studies in cell free assays provide
support for a role of miRNAs in inhibiting translation initiation (Mathonnet et al., 2007;
Wakiyama et al., 2007). In cell lysates, miRNAs repressed translation of m7G-capped
mRNAs but not mRNAs with an artificial unmethylated cap analog (ApppN) (Huntzinger
and Izaurralde, 2011). Further, miRNAs also did not repress the translation of mRNAs
containing an internal ribosome entry site (IRES) (Filipowicz et al., 2008; Mathonnet et
al., 2007; Wakiyama et al., 2007). The importance of m7G cap was further supported by
experiments with bi-cistronic reporters. The translational activity of the first cap-dependent
cistron was repressed by the endogenous let-7 miRNA. On the other hand, the second
cistron was unaffected by let-7 miRNA (Filipowicz et al., 2008; Pillai et al., 2005). Taken
together, these results suggest that cap-dependent translational initiation is repressed via
the miRNA-mRNA interaction.
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In agreement with a role for miRNAs inhibiting translation initiation, several
studies suggest that translation initiation factors play a critical role in miRNA mediated
repression (Iwakawa and Tomari, 2015; Kiriakidou et al., 2007; Mathonnet et al., 2007).
Supplementation or depletion of translation initiation factors in HEK293 cells, S2 cells and
in vitro cell-free translation system results in an attenuation of miRNA-mediated
translation repression (Fukao et al., 2014; Fukaya et al., 2014; Meijer et al., 2013). The
eIF4F complex is composed of three proteins: the cytoplasmic cap-binding protein eIF4E,
the scaffolding protein eIF4G and the RNA helicase eIF4A (Huntzinger and Izaurralde,
2011). Interestingly, Kiriakidou et al., (2007) demonstrated that central domains of AGO
proteins exhibit sequence similarity to the cap binding region of eIF4E (Kiriakidou et al.,
2007). The authors found that mutations of two crucial phenylalanines in this region
severely compromised the ability of tethered AGO proteins to repress reporter mRNAs.
These data suggest that AGO proteins might compete with eIF4E for m7G binding, block
the eIF4E-eIF4G interaction, abolish mRNA circularization and thus prevent the
translation of capped mRNAs (Hurschler et al., 2010; Kiriakidou et al., 2007).
More recently, studies using in vitro UV crosslinking indicate that miRNAs
dissociate the eIF4A protein from target mRNAs (Fukaya et al., 2014). eIF4A is an RNA
helicase normally involved in unwinding the secondary structures within target mRNA to
allow the 43S pre-initiation complex to scan the 5'UTR for translation (Jackson et al.,
2010). The authors showed that crosslinking of eIF4A to reporter mRNA was abolished in
the presence of miRNAs, whereas crosslinking of eIF4E showed no change. These results
indicate that miRISC targets eIF4A and not eIF4E for repression. The interaction between
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eIF4A proteins and miRISC components is proposed to block 43S scanning, resulting in
translation repression (Fukaya et al., 2014; Meijer et al., 2013; Ricci et al., 2013). Fukao et
al. used multiple approaches in HEK293 cells to show the significance of the dissociation
of eIF4A for miRNA-mediated translational repression. The authors used in vitro
translation assays to assess the effect of eIF4A proteins on target mRNA repression. In this
system, miRNAs failed to repress the translation of a Hepatitis C virus (HCV) IREScontaining reporter mRNA, which is known to be translated independently of eIF4A
(Fukao et al., 2014). Furthermore, HuD and silvestrol, which facilitate the retention of
eIF4As on mRNAs attenuated miRNA-mediated dissociation of eIF4As and translational
repression in vitro (Fukao et al., 2014). Future studies are needed to determine the
mechanism by which miRNAs dissociate eIF4A from target mRNAs. Taken together, these
results suggest that miRNAs can repress the translation of target mRNAs by inhibiting
formation of the pre-initiation complex. mRNAs that can undergo cap-independent
translation are immune to miRNA-mediated repression.
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Figure 9: miRNA mediated translation repression at the initiation stage.
The miRISC can inhibit translation initiation by interfering with the m7G cap recognition.
The miRISC proteins can either compete with the eIF4E for binding to the m7G cap or
impede the association of the 40S and the 60S subunit to form the 80S ribosomal subunit.
The interaction between the GW182 protein and the PABP protein can interfere with the
closed-loop mRNA configuration thus contributing to the translation repression at the
initiation stage. Alternatively, miRNAs can inhibit the association or activity of eIF4A (not
shown). These effects are likely to be miRNA/mRNA specific.
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1.4.2.2 miRNA-mediated translation repression at the elongation stage.
While extensive studies have suggested that miRNA can block translation at the
initiation stage, other data suggests that some mRNAs can also repress translation at
elongation stage. For example, some miRNA-bound mRNAs remain associated with
polysomes (Maroney et al., 2006; Nottrott et al., 2006; Olsen and Ambros, 1999; Petersen
et al., 2006; Seggerson et al., 2002; Wu and Belasco, 2008). Additional studies using IREScontaining reporters support miRNA repression after translation initiation. Lytle et al. and
Peterson et al. demonstrated that specific miRNAs can mediate repression of IREScontaining reporters (Lytle et al., 2007; Petersen et al., 2006). Because IRES elements
initiate translation independently of the m7G cap, these results indicate that miRNAs
repress translation at a step after cap recognition (Filipowicz et al., 2008). The
interpretation of polysome profiles of miRNAs and their associated target mRNAs have
led to several possible mechanisms by which miRNAs might regulate mRNA repression.
Some specific miRNAs are proposed to repress translation at the elongation step through
mechanisms including co-translational protein degradation, premature translational
termination, or ribosome stalling (Eulalio et al., 2008a; Filipowicz et al., 2008).
In support of the co-translational protein degradation model, sucrose sedimentation
assays demonstrated that some miRNAs co-sediment with target mRNAs and polysomes
but have no detectable protein product (Olsen and Ambros, 1999; Seggerson et al., 2002).
Based on these results, Nottrott et al. proposed that the nascent polypeptide chain might be
degraded co-translationally when miRNAs are bound to mRNAs (Figure 11; Nottrott et al.,
2006). However, the identity of the protease remains unknown and treatment with
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proteosome inhibitors did not restore protein expression of these reporters (Eulalio et al.,
2008a; Nottrott et al., 2006). Therefore, additional experiments are needed to validate this
mechanism. Petersen et al. proposed that some miRNAs cause premature termination of
ribosomes (known as “ribosome drop off”) (Petersen et al., 2006). To test this hypothesis,
the authors used a reporter with target sites for miRNAs. They performed a sedimentation
assay on the repressed reporter and an unrepressed mRNA followed by treatment with the
translation inhibitor hippuristanol. They found that ribosomes on repressed miRNA
reporter were released rapidly compared to the ribosomes on non-repressed mRNAs. These
correlative results suggest that miRNAs can lead ribosomes to fall off during translation
(Petersen et al., 2006).
An alternative mechanism for miRNA mediated repression at the post-initiation
stage was proposed by Chendrimeda et al. (Chendrimada et al., 2007). The authors
identified that eIF6 is involved in miRNA-mediated translation repression. Previous
studies have demonstrated that eIF6 plays a crucial role in the assembly of the 60S
ribosomal subunit. eIF6 inhibits the premature assembly of the 60S ribosomal subunits
with the 40S ribosomal subunit (Russell and Spremulli, 1978). The authors showed that
AGO proteins can repress translation by recruiting eIF6, which prevents the association of
the 60S and 40S ribosomal subunits (Chendrimada et al., 2007). However, the mechanism
by which AGO proteins recruit eIF6 to target mRNAs is not exactly clear. Moreover, the
involvement of eIF6 in this process has been challenged (Ding et al., 2008; Hurschler et
al., 2010). Knocking down eIF6 in Drosophila S2 cells did not affect miRNA mediated
repression (Fabian et al., 2010). eIF6 knockdown in C. elegans enhanced miRNA mediated
40

translation repression (Ding et al., 2008). Other studies have suggested that eIF6 may
instead affect either miRNA maturation or miRNA loading onto the miRISC complex
(Hurschler et al., 2010).
Taken together, these data provide evidence that for some mRNAs, miRNAs can
repress translation by releasing elongating ribosomes, as well as through co-translational
protein degradation. However, this data is contradictory to previous studies that suggested
that miRNAs primarily affected translation initiation. Different experimental conditions,
cell lines and reporters can explain some of these contradictions. However, it is also
possible that specific miRNAs can utilize both pre-initiation and post-initiation translation
inhibition mechanisms to regulate translation of a wider variety of mRNAs. This versatility
could especially be useful in physiological conditions where cap-dependent translation is
limited or when certain mRNAs utilize both cap-dependent and IRES-dependent
translation. Further investigation into the processes is required.
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Figure 10: miRNA mediated translation repression at the elongation stage.
The miRISC proteins have been suggested to either slow the movement of ribosomes along
the target mRNA or to induce ribosomal drop-off. The premature dissociation of ribosomes
is proposed to cause the ribosomes to drop off the target mRNA. The precise mechanisms
underlying these models are currently not clear.
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Figure 11: miRNA mediated co-translational protein degradation.
Nascent polypeptides are proposed to be degraded co-translationally via the association of
specific miRNAs with target mRNAs. However, the identity of the putative protease
involved in this process remains unknown.

43

1.4.2.3 Role of GW182 in mediating translation repression.
The GW182 family of proteins is important for miRNA-mediated gene silencing
(Braun et al., 2013; Eulalio et al., 2008b). GW182 designates target mRNAs for translation
repression or degradation through multiple protein-protein interactions (Braun et al., 2013;
Fabian and Sonenberg, 2012). Besides interacting with the AGO proteins, GW182 interacts
with Poly-A binding protein (PABP) and the CCR4-NOT deadenylase complexes to
contribute to miRNA-induced translation repression (Eulalio et al., 2008a; Fabian and
Sonenberg, 2012; Fabian et al., 2009, 2010).
Several studies suggest that the PABP–GW182 interaction is important for miRNA
mediated gene silencing (Fabian et al., 2009; Huntzinger et al., 2010; Jinek et al., 2010;
Zekri et al., 2009). One model posits that GW182 competes with eIF4G for PABP binding,
thereby interfering with the PABP-eIF4G association, mRNA circularization, and capdependent translational initiation (Fabian et al., 2009; Zekri et al., 2009). A second model
proposes that GW182–PABP interaction may reduce the association between PABP and
the poly-A tail, leading to translation repression (Huntzinger et al., 2010). In contrast to
these observations, several other studies have demonstrated that GW182-PABP interaction
does not affect miRNA-mediated repression. Notably, in S2 cell lysates and zebrafish
embryos, depletion of PABP or addition of PABP-binding protein 2 (PAIP2), which inhibit
both the eIF4G–PABP and the PABP–poly (A) interactions, did not affect miRNAmediated translational repression (Fukaya and Tomari, 2011; Iwakawa and Tomari, 2015;
Mishima et al., 2012). These results suggest that although PABP’s interaction with GW182
is important for miRNA-mediated repression, inhibition of GW182-PABP interaction is
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likely not the only mechanism for miRNAs to mediate translation repression (Iwakawa and
Tomari, 2015).
Previous studies in S2 cells and human cells demonstrate that the GW182 proteins
act as docking platforms to recruit CCR4-NOT1 and PAN2-PAN3 deadenylase
components to regulate deadenylation of polyadenylated mRNAs (Braun et al., 2011;
Chekulaeva et al., 2011; Fabian et al., 2012). Interestingly, knockdown of the deadenylase
components severely impairs GW182-meditated repression of non-adenylated mRNAs
(Braun et al., 2011; Chekulaeva et al., 2011). These results led to the model that
deadenylase complexes facilitate a deadenylation-independent mode of translation
repression (Braun et al., 2013; Fabian and Sonenberg, 2012). However, mechanistic details
on how GW182 might either recruit deadenylase components to mediate deadenylation or
how GW182 mediates translation repression independent of deadenylation remain elusive
(Fabian et al., 2010). Recent structural and biochemical studies demonstrated that the
deadenylase NOT1 interacted directly with the DEAD-box RNA helicase DDX6. DDX6
is believed to function primarily as a translation repressor in mammalian cells (Chen et al.,
2014b; Mathys et al., 2014; Rouya et al., 2014). Therefore, the GW182 proteins might
recruit DDX6 to target mRNAs through an interaction with the CCR4-NOT1 complex
(Iwakawa and Tomari, 2015). Recent studies also indicate that CCR4-NOT1 recruits the
eIF4E-binding protein 4E-T through interaction with DDX6 (Nishimura et al., 2015;
Waghray et al., 2015), and 4E-T represses translation by binding to eIF4E proteins and
inhibit cap-dependent translation initiation. However, further studies are needed to identify
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the specific step of translation blocked by the interaction between GW182 and DDX6
(Wilczynska and Bushell, 2014).
1.4.2.4 Compartmentalization of miRNA-mediated repression in P bodies.
mRNAs subject to translational repression are localized to cytoplasmic RNP
granules knows as P bodies along with miRNAs and the miRNA machinery in eukaryotic
cells (Eulalio et al., 2007a; Liu et al., 2005; Parker and Sheth, 2007). Cellular components
that are involved in miRNA function, including AGO1, GW182, the CCR4-NOT1
deadenylase complex, the decapping enzyme DCP2, decapping enhancers (DCP1, EDC3)
and the RNA helicase DDX6/RCK/ME31B, also localize to P bodies (Anderson and
Kedersha, 2006; Eulalio et al., 2007a; Parker and Sheth, 2007). P bodies are devoid of
ribosomal subunits and translation initiation factors (Filipowicz et al., 2008; Liu et al.,
2005; Mitchell and Parker, 2014; Teixeira et al., 2005). Previous studies have indicated a
correlation between miRNA-mediated translational repression and the accumulation of
target mRNAs in P bodies (Bhattacharyya et al., 2006; Filipowicz et al., 2008; Liu et al.,
2005; Pillai, 2012). Specifically, miRNAs, AGO1 and GW182 interact with other P body
components, and the knockdown of ME31B or other decapping enhancers weakens
miRNA-mediated translation repression (Chu and Rana, 2006; Fabian et al., 2010).
Importantly, a functional miRNA pathway is important for P body formation (Eulalio et
al., 2007c; Filipowicz et al., 2008), and inhibition of miRNA biogenesis or depletion of
GW182 or AGO1 protein results in a dispersal of P bodies in mammalian and S2 cells
(Filipowicz et al., 2008). However, knockdown of some P-body components (for example
LSM1, LSM3) result in the dispersal of P-bodies but have no effect on miRNA function
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(Filipowicz et al., 2008). Therefore, P bodies are likely not required for miRNA function,
and their formation is a consequence rather than the cause of translational silencing (Chu
and Rana, 2006; Eulalio et al., 2007c).
1.5 Role of FMRP in miRNA-mediated repression.
Previous studies have demonstrated that FMRP interacts with some miRNAs and
core miRISC components to regulate translation. This association provides selective,
bidirectional, spatial and temporal control for regulating mRNA translation (LiuYesucevitz et al., 2011; Muddashetty et al., 2011). FMRP is genetically and biochemically
linked to the miRNA pathway (Edbauer et al., 2010; Li and Jin, 2009). dFMRP and
mammalian FMRP interact directly with Dicer1, AGO1, and the miRISC-associated RNA
helicase MOV10 (Cheever and Ceman, 2009; Jin et al., 2004b; Kenny et al., 2014; Li and
Jin, 2009; Loffreda et al., 2015; Plante et al., 2006). Moreover, translationally repressed
mRNAs along with FMRP, miRNAs, core miRISC components (AGO1, GW182) and
other RNA binding proteins are localized in motile neuronal mRNA granules in axons and
dendrites (Barbee et al., 2006; Muddashetty et al., 2011).
In vitro studies have indicated that FMRP can also act as an acceptor of miRNAs derived
from Dicer processing of pre-miRNAs through its KH2 domain (Plante et al., 2006).
Moreover, phosphorylation of FMRP inhibits its association with Dicer (Cheever and
Ceman, 2009). These results suggest that cooperation between Dicer and FMRP is
important for miRNA function and mRNA regulation. KH domains of FMRP have been
demonstrated to be crucial for the association of FMRP and miRISC components. A
specific mutation in the KH2 domain of FMRP (I304N) causes a severe form of FXS. This
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mutation causes defects in association with ribosomes and target mRNA (Caudy et al.,
2002). The analogous mutation (I307N) in Drosophila has been shown to disrupt the
association between FMRP and AGO proteins (Caudy et al., 2002; Loffreda et al., 2015).
These results suggest the importance of a direct interaction between FMRP and miRISC
components in the function of FMRP- and miRNA-mediated repression in cells.
Recent studies have proposed that modification of the secondary structure of
mRNA can facilitate the interaction between FMRP and miRISC components. The 3’UTRs
of mRNAs contain secondary structures and have embedded seed regions for miRNAs.
FMRP was shown to interact with an RNA helicase, MOV10, which is a component of the
miRISC (Kenny and Ceman, 2016; Kenny et al., 2014). FMRP recruits MOV10 to target
mRNA for unwinding the secondary structure for subsequent access of miRISC complex
to repress target mRNA (Kenny and Ceman, 2016; Kenny et al., 2014). Taken together,
these results support a model in which the binding of FMRP to target mRNAs contributes
to the ability of miRISC to repress target mRNAs (Banerjee et al., 2018; Edbauer et al.,
2010; Kenny et al., 2014; Li et al., 2014; Muddashetty et al., 2011).
Other studies have demonstrated that a functional relationship between FMRP and specific
miRNAs is essential to repress target mRNAs (Li and Jin, 2009). It is unclear if this
interaction involves the RISC but it is important for proper synaptic structure and function
(Edbauer et al., 2010; Kenny and Ceman, 2016; Loffreda et al., 2015). Edbauer et al.
demonstrated that FMRP associates with miR-125b and miR-132 to control dendritic spine
morphology in mice (Kenny and Ceman, 2016). The authors showed that overexpression
of miR-125b and miR-132 resulted in dendritic spine defects in hippocampal neurons.
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Importantly, a knockdown of FMRP rescued these phenotypes in mice, suggesting that
FMRP interacts with specific miRNAs to control dendritic spine development (Banerjee et
al., 2018; Edbauer et al., 2010; Richter et al., 2015).
Additional studies have demonstrated the existence of a cooperative mechanism
between FMRP and miRISC components to reversibly and selectively regulate synaptic
mRNAs in response to mGLuR signaling (Loffreda et al., 2015; Muddashetty et al., 2011).
FMRP recruits the miR-125a-AGO2 complex to the 3'UTR of the PSD-95 mRNA to
repress translation of the postsynaptic density protein 95 (PSD-95) at the synapse in
response to mGLuR stimulation. Phosphorylation of FMRP at a specific serine residue
(Ser499) results in the formation of the miR-125a-AGO2 inhibitory complex on PSD-95.
Dephosphorylation of FMRP, on the other hand, relieves PSD-95 from repression (Kenny
and Ceman, 2016; Muddashetty et al., 2011). Similarly, dephosphorylation of FMRP by
the specific phosphatase 2A (PP2A) plays an important role in the bidirectional regulation
of mRNA translation in neurons (Loffreda et al., 2015).
Although previous studies demonstrated that interactions between FMRP and
miRNA pathway are critical to regulating translation of target mRNAs, the mechanism of
FMRP’s interaction with various miRNA components is not well understood. Studying this
interaction will shed light on an important function of FMRP in cells. Because FMRP
deficiency and loss of function is implicated in FXS, understanding of the function of
FMRP in miRNA-mediated translation repression (or vice versa) has the potential to
identify underlying mechanisms that contribute to the pathology of FXS in patients.
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1.6 Summary
Previous studies indicate that FMRP interacts biochemically and genetically with
Dicer1 and miRISC proteins such as AGO1 and MOV10 (Caudy et al., 2002; Jin et al.,
2004b; Kenny et al., 2014). FMRP is also known to associate with specific miRNAs to
regulate translation repression (Edbauer et al., 2010; Muddashetty et al., 2011). These
interactions are required to control normal synaptic development in mammals and flies. A
growing amount of evidence points towards a cooperative mechanism of FMRP-mediated
translation repression of target mRNAs via miRNAs. However, the details of this
mechanism remain elusive. The underlying objective of this thesis is to explore the
mechanism of FMRP-mediated translation repression via the miRNA pathway. To
address this, we used Drosophila as our model as it offers multiple advantages compared
to the other model organisms. Drosophila are easier to maintain, less expensive, have a
shorter lifespan and generation time with a completely sequenced genome (Drozd et al.,
2018). Moreover, dFMRP, the only Drosophila ortholog of human FMRP, is highly
conserved with a similar amino acid sequence, RNA-binding properties and biochemical
function in vivo (Bhogal and Jongens, 2010). dFmr1-null flies recapitulate many of the
FXS phenotypes, such as defects in memory, social behavior, circadian rhythmicity and
sleep (Weisz et al., 2015). Further, dFmr1 nulls display defects in synaptic growth
mimicking dendritic spine overgrowth in FXS patients (Weisz et al., 2015).
In this study, we have used an in vitro system to study FMRP mediated translation
control by using a translational reporter system in Drosophila S2 cells. Our results suggest
that FMRP requires AGO1 and GW182 to mediate translation repression when FMRP is
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tethered to a luciferase reporter mRNA. We have also examined the role of the RNA
binding domains (RBDs) of tethered FMRP in translation repression and found that KH1
and 2 domains contribute to its ability to repress translation. Further, we show that
untethered FMRP can repress translation of the reporter by recognizing and binding to a
small stem-loop structure within its 3’UTR. These results point towards the importance of
structural elements in target mRNAs for FMRP mediated translation regulation.
Remarkably, our analysis suggest role for FMRP in the recruitment of miRNAs to a target
mRNA for translation repression, suggesting a role for FMRP in miRNA-mediated
repression.
FMRP associates with mRNAs as part of a large mRNP complex in distinct
cytoplasmic foci (Kedersha and Anderson, 2007; Kenny and Ceman, 2016). Therefore, we
also examined the intracellular localization of FMRP with miRISC components within S2
cells and the larval CNS. Our results demonstrate that FMRP is present in same cells as
core miRISC components. We performed co-immunoprecipitation to test the direct
association of FMRP with core miRISC components. Our results indicate a strong
association of FMRP with AGO1 and a weak association of FMRP with GW182 under low
salt conditions. Under high salt conditions, we found a dissociation of FMRP with GW182
with not much effect on the association of FMRP-AGO1. Therefore, the association
between FMRP and AGO1 appears to be stronger than GW182. Next, we used the larval
neuromuscular junction (NMJ) to study genetic interactions between FMRP and AGO1 or
GW182. We demonstrate that genetic interactions of FMRP with AGO1 and GW182 are
crucial to regulate synaptic structure at the larval NMJ.
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FMRP-associated mRNAs that are targeted for translation repression are found to
localize in cytoplasmic foci such as P-bodies and stress granules. Previous studies also
indicate that miRISC regulates repression by targeting mRNAs for repression via
deadenylation followed by translation repression in P bodies (Braun et al., 2013; Eulalio et
al., 2007c; Fabian and Sonenberg, 2012). Therefore, we screened for a genetic interaction
between the key proteins involved in deadenylation and repression: CCR4, NOT1, and
PABP, in order to identify the downstream mechanism for FMRP-miRISC mode of
repression. We demonstrate that FMRP is present in the same cells as the components of
deadenylase enzyme (CAF1, CCR4, and NOT1) within larval CNS. However, FMRP does
not interact genetically with CCR4, NOT1 or PABP to control synaptic morphology. These
results suggest that FMRP does not interact with CCR4, NOT1 or PABP within the same
pathway. Therefore, FMRP-GW182 utilizes an alternative mechanism to control synaptic
structure and morphology in Drosophila.
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CHAPTER TWO: METHODS
2.1 Key resources table
2.1.1Reagents and Chemicals
Shields and Sang media

Sigma Adrich

S-8398

Effectene transfection reagent

Qiagen

301425

Dual-luciferase reporter assay system

Promega

E2940

Corning Flat bottom, non-treated, white Fisher Scientific

3912

polystyrene well plate
MEGAscript T7TM Transcription kit

Fisher Scientific

Q5 polymerase hot start high-fidelity New England Biolabs

AM1333
M0493S

DNA polymerase
RNeasy mini kit

Qiagen

74104

Ambion DNAase I (RNase free)

Fisher Scientific

AM1906

Betamercaptoethanol

Bio-Rad

161-0710

2x Laemmli sample buffer

Bio-Rad

161-0737

SouthernBiotech

Dapi-Fluoromount-G Fisher Scientific

OB010020

clear mounting media
Pierce protease inhibitor tablets- EDTA Fisher Scientific

A32955

free
iQ SYBR green supermix

Bio-Rad
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170-8880

RNA to cDNA eco-dry premix (double Clonetech

639549

primed)
RNAeasy mini kit

Qiagen

74104

Super signal west dura substrate

Fisher Scientific

34076

GFP trap beads

Chromotek

Gtmak-20

RNase inhibitor tablets

Fisher Scientific

AM2694

NP-40 Surfact-Amps Detergent solution

Fisher Scientific

28324

Gateway cloning system

Fisher Scientific

K2400-20
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2.1.2 Experimental models: Cell lines
Cell line
S2 cells

Source
Drosophila Genomics Resource Center

Identifier
CVCL-Z232

(DGRC)

2.1.3 Experimental models: Fly strains
Fly strains

Source

Identifier

w1118

Bloomington Drosophila Stock Center

3605

dfmr1∆113

Bloomington Drosophila Stock Center

6929

Ago1I(2)k00208

Bloomington Drosophila Stock Center

10470

gw1

(Schneider et al., 2006)

N/A

TwinGS12209

Kyoto Stock Center (DGGR)

203904

Not1M107631

Bloomington Drosophila Stock Center

44201

pAbpk10109

Bloomington Drosophila Stock Center

10970

Dcp1442p

(Lin et al., 2006)

N/A

elav-Gal4

Bloomington Drosophila Stock Center

8765

w1118;ActGFP,unc13[In(

Bloomington Drosophila Stock Center

9549

UAS-Dcr1RNAi

Bloomington Drosophila Stock Center

34826

UAS-AGO1 RNAi

Bloomington Drosophila Stock Center

33727

UAS-gawky RNAi

Bloomington Drosophila Stock Center

34796

4)ciD,ci[D]pan[ciD]
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2.1.4 DNA constructs
DNA constructs

Source

Identifier

pAc5.1C- FLuc-Stop-5BoxB

Addgene

21301

pAc5.1C-RLuc-Stop-V5His6

Addgene

21182

pAc5.1B-lambdaN-HA

Addgene

21302

pAc5.1B-lambdaN-HA

This study

N/A

FMRP
pAFW-Ago1

(Kawamata et al., 2009)

N/A

pAFW-Ago2

(Iwasaki et al., 2010)

N/A

pAFW-GW182

This study

N/A

pAFW-Dicer1

This study

N/A

pAc5.1B-EGFP

Addgene

21181

pAc5.1B-EGFP-DmAGO1

Addgene

22768

pAc5.1B-EGFP-DmGW182

Addgene

22419

pAc 5.1(dV5-HisA)

Fisher Scientific

V411020

pAc 5.1 miR-958

This study

N/A

pAc 5.1 miR-13b

This study

N/A

pAc 5.1 miR-33

This study

N/A

pAc 5.1 miR-2b

This study

N/A

pAc 5.1 miR-2a

This study

N/A

pAc 5.1 miR-279

This study

N/A

pAc 5.1-FLuc-ppk 3’UTR

This study

N/A
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pAc 5.1-FLuc-chic 3’UTR

This study

N/A

pAc 5.1-FLuc-arc 3’UTR

This study

N/A

pAc 5.1-FLuc- rac1 3’UTR

This study

N/A

pAc 5.1-FLuc- tral 3’UTR

This study

N/A

pAc5.1B-lambdaN-HA-

This study

N/A

This study

N/A

This study

N/A

This study

N/A

This study

N/A

This study

N/A

∆RGG FMRP
pAc5.1B-lambdaN-HA∆KH0 FMRP
pAc5.1B-lambdaN-HA∆KH1/2 FMRP
pAc5.1B-EGFP-∆RGG
FMRP
pAc5.1B-EGFP-∆KH0
FMRP
pAc5.1B-EGFP-∆KH1/2
FMRP
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2.1.5 Oligonucleotides
Oligonucleotide name
Forward

primer

to

Sequence (5’to 3’)
amplify

the CACCTGCCGCCCGGCCAGTGGAA

Tral3’UTR
Reverse primer to amplify the Tral AGTAAATAATTTCAGTTATAAAATT
3’UTR

ATAT

Forward primer to amplify the ppk CACCTCGATGGTCTTAAAGGCCGA
3’UTR

AAG

Reverse primer to amplify the ppk GCGAACACATTTTTTATTGTCGTG
3’UTR
Forward primer to amplify the chic CACCCCGCTTCCGTGGTAGAGAAA
3’UTR

CT

Reverse primer to amplify the chic TGACTTTGGGAACCGCGATA
3’UTR
Forward primer to amplify the rac1 CACC
3’UTR

AAGAGTTAGACAGTTGGTCGG

Reverse primer to amplify the rac1 CCTTTTATTATGCTTTATTGATTTCC
3’UTR
Forward primer to amplify the arc CCTTTTATTATGCTTTATTGATTTCC
3’UTR
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Reverse primer to amplify the arc GTCCCATCCACCCCATAAA
3’UTR
Forward primer for RNAi against TAATACGACTCACTATAGGG
Dicer1

CGGAACACGATTATTTGCCT

Reverse primer for RNAi against Dicer1

TAATACGACTCACTATAGGG
CGCAACACGGTGACAATATC

Forward primer for RNAi against AGO1 TAATACGACTCACTATAGGG
ATTTGATTTCTATCT ATGCAGCCA

Reverse primer for RNAi against AGO1 TAATACGACTCACTATAGGGGCCCT
G GCCATGGCACCTGGCGTA

Forward primer for RNAi against TAATACGACTCACTATAGGG
GW182

AATCCAAGTAATCCTATAAGCAG

Reverse primer for RNAi against TAATACGACTCACTATAGGG
GW182

ATTGCTTGCTTTGCTTAATGA

Forward primer for RNAi against TAATACGACTCACTATAGGGT
Armitage

TGCGCCAAATTTGTTTGAC
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Reverse primer for RNAi against TAATACGACTCACTATAGGGA
Armitage

AGAAATCCTCGCCCATTAC

Forward primer for RNAi against EGFP TAATACGACTCACTATAGGGAA
GAAATCCTCGCCCATTAC
Reverse primer for RNAi against EGFP TAATACGACTCACTATAGGG
TGCTCAGGTAGTGGTTGTCG
Forward primer for RNAi against AGO2 TAATACGACTCACTATAGGG
AGGATGGAGCAACTCAGGT
Reverse primer for RNAi against AGO2 TAATACGACTCACTATAGGG
ATTCTAAACTGAGGAATAATCACA
Forward primer for qRT-PCR of the AAACGCTTCCACCTACCAGG
FLuc reporter
Reverse primer for qRT-PCR of the TGATCAGAATGGCGCTGGTT
FLuc reporter
Forward primer for qRT-PCR of the TTTACATGGTAACGCGGCCT
RLuc
Reverse primer for qRT-PCR of the TAATACACCGCGCTACTGGC
RLuc
Forward primer for amplifying miR-33a CACC GCTGTGCTGCGAGCTAAGAT
Reverse primer for amplifying miR-33a

ACACAAGCTCAGGTTACGGA

Forward primer for amplifying miR-13b CACC CCGTCATAAATCGGTTTGG
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Reverse primer for amplifying miR-13b ATAGCAAAATGTGACCCGTG
Forward primer for amplifying miR-279 CACC
CGTACGCCTATGTGTATGTGTG
Reverse primer for amplifying miR-279 ATCGCTCTTCCTTTTGGGC
Forward primer for amplifying miR-2a

CACC
TAAGTCTGAGGTGCCAGTCCAC

Forward primer for amplifying miR-2b

CACC
CAGAAAGGGGAGTGATGTTC

Reverse primer for amplifying miR-2b

GTTGATTTCTTGCGCCTATG

Forward primer for EGFP-Dicer1

GGTGGTGCGGCCGC
ATGGCGTTCCACTGGTGCGAC

Reverse primer for EGFP-Dicer1

GGTGGTCCGCGG
TTAGTCTTTTTTGGCTATCAAGCC
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2.1.6 Antibodies
Antibody

Source

Identifier

Mouse anti-FMRP (6A15)

Abcam

AB-10299

Rabbit anti-Dicer1

Abcam

AB-4735

Rabbit anti-AGO1

Abcam

AB-5070

Rabbit anti-AGO2

Abcam

AB-5072

Guinea-pig anti-GW182

(Schneider et al., 2006)

N/A

Mouse anti-Armitage

(Saito et al., 2010)

N/A

Rabbit anti- CCR4

(Temme et al., 2004)

N/A

Rabbit anti- NOT1

(Temme et al., 2010)

EG 314

Rabbit anti-CAF1

(Temme et al., 2004)

N/A

Mouse anti- HA (6E2)

Cell Signaling Technology

2367

Rat anti-EGFP (3H9)

Chromotek

ABIN- 398304

Rabbit anti-GFP

Torey Pines

TP401

Mouse anti-FLAG (M2)

Sigma-Aldrich

F3165

Mouse anti-Actin
Anti-discs large (4F3)

Abcam
Developmental

AB-8224
Studies AB-528203

Hybridoma Bank
Horse anti mouse IgG HRP- Cell Signaling Technology

7076

linked antibody
Goat anti-rabbit IgG HRP- Cell Signaling Technology
linked antibody
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7074

Donkey anti-guinea pig IgG Jackson

Immunoresearch 706-035-148

Laboratories
Alexa Flour 488 goat anti- Invitrogen

A-2534069

mouse IgG
Alexa Fluor 568 goat anti Invitrogen

A-3534072

rabbit IgG
Alexa Fluor 594 goat anti Invitrogen

A-11076

guinea pig IgG
Alexa Fluor 647 goat anti- Jackson
HRP

Immunoresearch

Laboratories
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123-605-021

2.1.7 Media and buffer composition
Media
M3 media (10 L)

Composition
393.6 g Shields and Sang powdered
medium,

5g

KHCO3,

10g

yeast

extract,25g bactopeptone (pH 6.6)

Buffers for western blot

Composition

S2 lysis buffer

50mM Tris-HCl (pH 7.4), 150mM
NaCl, 1mM EDTA, 0.1% Triton, 0.5%
NP40, supplemented with EDTA free
protease inhibitor tablets

Sample buffer

2X

Lamelli

buffer

and

ß-

mercaptoethanol
10 X TGS (Tris Glycine SDS) Running 250 mM Tris, 1.92M Glycine and 1% w/v
buffer

SDS

1X Transfer buffer (2 L)

6.0 g Tris, 28.8 g Glycine, 200ml
Methanol, 1.6ml water

1X Tris-buffered saline (1X TBS)

150mM NaCl, 50mM Tris-Cl (pH 7.5)

TBST (Tris-buffered saline, 0.1% 100 mL of TBS 10X – 900 mL of distilled
Tween 20) -(1L)

water – 1 mL Tween 20
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Blocking buffer

1X TBST with 5% w/v dry milk

Gentle stripping buffer (1L)

15 g glycine, 1 g SDS, 10 ml Tween20
(pH 2.2)

Harsh stripping buffer (0.5 L)

20 ml 10% SDS, 12.5 ml Tris HCl (pH
6.8), 67.5 ml water, 0.8ml of ßmercaptoethanol

Buffers for co-immunoprecipitation

Composition

1X PBS (Phosphate buffered saline)

0.137M NaCl, 0.0027M KCl, 0.01M
Na2HPO4, 0.0018M KH2PO4

(pH 7.4)
S2 lysis buffer

150mM NaCl, 0.5% NP40, 20mM
HEPES (pH 7), 2mM MgCl 2 , 1mM
DTT supplemented with EDTA free
protease inhibitor tablets and RNAase
inhibitor

Low-salt wash buffer

150 NaCl, 0.5% NP40, 20mM HEPES
(pH 7), 2mM MgCl2 , 1mM DTT

High- salt wash buffer

300mM NaCl, 0.5% NP40, 20mM
HEPES(4-(2-hydroxyethyl)-1piperazineethanesulfonic

acid),

MgCl 2 , 1mM DTT (pH 7),
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2mM

2X SDS elution buffer

4%

SDS,

20%

bromophenol

glycerol,

0.004%

0.125M

Tris-Cl

blue,

(pH6.8), 10% ß-mercaptoethanol

Buffers for CNS dissections

Composition

1X PBS (Phosphate buffered saline) (pH 0.137M NaCl, 0.0027M KCl, 0.01M
7.4)

Na2HPO4, 0.0018M KH2PO4

Permeabilization buffer (PBS-T)

1X PBS with 0.3% Triton X-100

Blocking buffer

1X PBS-T with 5% Normal Goat
Serum

and

2%

Bovine

Serum

Albumin (BSA)

Buffers for NMJ dissections

Composition

Calcium-free HL-3 buffer (1L) (pH 7.2)

70mM NaCl, 5mM KCl, 20mM
MgCl2.6H2O,10mMNaHCO3,
115mM Sucrose, 5mM Trehalose,
5mM HEPES

Permeabilization buffer (PBS-T)

1X PBS with 0.1% Triton X-100

Blocking buffer

1X PBS-T with 5% NGS and 2%
BSA.
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2.1.8 Software and Algorithms
Software

URL

Flybase

http://flybase.org/

RNAfold

http://rna.tbi.univie.ac.at/cgibin/RNAWebSuite/RNAfold.cgi

SnapDragon

http://www.flyrnai.org/cgi-bin/RNAi_find_primers.pl

PITA

https://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html

LarvaTrack

https://github.com/plredmond/larva-tracker

algorithm
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METHOD DETAILS
2.2 DNA Constructs
For tethering assays, we obtained pAc5.1C- FLuc-Stop-5BoxB, pAc5.1C- RLucStop-V5His6 and pAc5.1B-lambdaN-HA vectors from Prof. Elisa Izzauralde via Addgene
as listed in Table 2.1 (Behm-Ansmant et al., 2006; Rehwinkel et al., 2005). To generate
the pAc5.1B-λN-HA FMRP, the full sequence of FMRP was amplified by PCR and cloned
into the pAc5.1 backbone vector in frame with the λN-HA tag. The pAc5.1C-FLuc-Stop3XBoxB, pAc5.1C-FLuc-Stop-1XBoxB and pAc5.1C-FLuc-Stop were generated by
removing the 5BoxB sequence from the pAc 5.1C-FLuc-Stop-5XBoxB and cloning oligos
containing the indicated number of BoxB repeat sequences.
Snapdragon was used to design optimal RNAi primers with no off-target effects
against Dicer1, AGO1, AGO2, Armitage and GW182 in S2 cells. Templates for dsRNA
synthesis were either cDNA isolated from Drosophila S2 cells or cDNA clones obtained
from DGRC. cDNAs were PCR amplified using primers listed in Table 2.1.5. The
amplified products were extended to have convergent T7 promoters. Following cDNA
clones were obtained from DGRC: AGO1 (CG6671) and GW182 (CG31992). Dicer1,
AGO2, and Armitage were amplified using primers listed in Table from cDNA of
Drosophila S2 cells. The EGFP sequence was amplified via PCR from the pAC5.1-EGFP
plasmid. Predicted dsRNAs were 300-566 nucleotide long and corresponded to the coding
sequences for control EGFP dsRNA, GW182, AGO1, AGO2, Armitage, and Dicer1. PCR
products were isolated, purified and transcribed into dsRNA using MEGAscript T7TM
Transcription Kit. Transcription reactions were treated with DNAase and purified using
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phenol-chloroform extraction. dsRNAs were ethanol precipitated and resuspended in
nuclease-free water. Agarose gel and UV absorbance values were used to assess the yield
and the quality of dsRNAs.
The 3'UTR sequences of known FMRP target mRNAs including Trailer-hitch,
pickpocket, Rac, Chicadee, Arc1 were amplified by PCR and cloned into pENTR and
subsequently into pAc5.1-FLuc2 [dPolyA] destination vector using the Gateway system.
These constructs were used for transfection in S2 cells for analysis of repression by FMRP.
For primer sequences, refer to Table 2.1.4.
For miRNA expression in S2 cells, PCR primers were designed to amplify a
sequence 200 nucleotide sequence upstream and downstream of each miRNA hairpin from
genomic DNA to allow proper processing. The PCR products of miR-958, Bantam, miR13b, miR-33, miR-2b, miR2a were cloned into pENTR and then into the pAC5.1 (dV5HisA) expression vector for transfections in S2 cells as we have previously described
(Nesler et al., 2013). The primers are described in Table 2.1.4.
For the pAFW-GW182 construct, cDNA clone obtained from DGRC was used to
amplify GW182 using primers described in table 2.1.4. The product was cloned into the
pENTR vector as an entry vector for LR recombination into the pAFW expression vector
(Drosophila Gateway Vector Collection, Carnegie Institution). Using primers listed in table
2.1.4, Dicer1 was amplified from the cDNA of S2 cells and inserted into the sites between
Not1 and SacII sites in the pAc5.1-EGFP plasmid to generate pAc5.1-EGFP Dicer1.These
plasmids were used for S2 cell transfection.
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The pAc5.1B plasmids containing EGFP-FMRP and deletions for EGFP FMRP
(∆RGG), FMRP(∆KH1/2), FMRP(∆KH0) were cloned as described (Gareau et al., 2013b).
The first PCR product was amplified from pAc5.1 λN-HAFMRP using oligos with BamHI
and HindIII sites, and the second PCR fragment was amplified using oligos with BamHI
and EcoR1 sites. The amplified products were digested and ligated into pAc5.1 EGFP
FMRP construct, previously digested with HindIII and EcoRI, to generate pAc5.1 EGFP
FMRP(∆KH1/2) and FMRP(∆KH0) constructs respectively. To generate the pAc5.1 EGFP
FMRP(∆RGG), the first PCR product was amplified from pAc5.1 λN-HAFMRP using
oligos with HindIII and EcoR1 sites at the end and the second product was amplified using
primers with BamHI and HindIII sites. These PCR products were digested with restriction
enzymes for ligation into the pAc5.1 EGFP FMRP previously digested with EcoRI and
HindIII for directional cloning.
2.3 S2 Cell Culture and Transfection
Drosophila S2 cells were maintained in vented 75cm2 cell culture-treated flasks
and cultured in M3 media, supplemented with 10% FBS, 1% Penicillin-Streptomycin and
Fungizone. Cells were incubated at room temperature in an incubator and passaged every
72 hours at a ratio of 4 ml cells to 12 ml cell culture media. The day before transfection,
cells were split into 250 ml suspension flasks in M3 media without Fungizone at 1:1
dilution.
On the day of transfection, cells were vigorously suspended and detached from
tissue culture flasks with a pipette. Hemocytometer was used to determine the number of
viable cells in the original cell suspension. The volume of cell suspension corresponding
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to a density of 1 x 106 cells/ml was determined. Cells were centrifuged at 2,500 rpm for 3
minutes and resuspended in 1X PBS for 15 minutes followed by resuspension in an
appropriate volume of cell culture media (0.8ml/well). All transfections were performed in
three biological replicates in 12 well plates using Effectene transfection reagent.
Manufacturer's instructions were followed to prepare transfection mixtures, as described
below.
Briefly, the transfection mixture contained reporter plasmid, plasmid encoding
gene of interest, control plasmids, DNA condensation buffer (Buffer EC), Enhancer
solution and Effectene solution. After incubation for 10 minutes, 1.5 ml of media was
added directly to the tubes and mixed with a pipette. The cells were dispensed drop-wise
(500ul) into individual wells while gently swirling the plate. Post-transfection, the cells
were incubated for 72 hours until harvested, and were processed for gene expression or
biochemical analysis as described below.
2.3.1 Tethering Assays
In tethering experiments, cells were co-transfected with 0.05µg of the FLuc-BoxB
reporter plasmid, 0.2µg of RLuc plasmid, 0.25µg of plasmid-expressing the λN-HA protein
per well of a 12-well plate. The plasmid expressing the λN-HA-tagged FMRP was added
in increasing amounts from 0.125µg to 0.5µg per well. The modified FLuc reporter with 3
(FLuc-3xBoxB), 1(FLuc-1xBoxB) or no BoxB sites (FLuc-0xBoxB) was transfected using
similar procedure and concentration as described above. At least three independent
transfection experiments were performed, each with three technical replicates.
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2.3.2 Assays with untethered FMRP
Transfection assays with untethered FMRP (FMRP lacking λN-HA tag) followed
a similar transfection procedure as described above. In assays with miR-958, transfection
mix contained FLuc-Box B reporters mainly 0.05µg of FLuc-1XBoxB or FLuc-0XBoxB
reporter, 0.2µg of RLuc plasmid, 0.25µg of empty vector (no miRNA control) and 0.5µg
of untethered FMRP.
The entire SV40-3'UTR sequence of the FLuc-BoxB reporter was replaced by the
3'UTR of ppk, chic, tral, rac, and arc as described previously. These reporters were cotransfected with increased concentration of untethered FMRP (0.125-0.5 µg), 0.2 µg of
RLuc, and 0.25 µg of λN-HA control.
2.4 Luciferase Assays
The FLuc and RLuc luciferase activities were measured sequentially with the DualLuciferase Reporter Assay System. The ratio of the FLuc/RLuc was measured for each
well in three technical replicates on an infinite M1000 plate reader.
For the measurement of FLuc activity, 75µl of cell suspension was dispensed into
the wells of a 96-well plate, followed by the addition of an equal volume of Dual-Glo®
Reagent.

FLuc values were quenched with Stop & Glo® reagent, followed by the

measurement of the RLuc activity in the same wells. The FLuc/RLuc ratio for each sample
was normalized to the ratio of the well with transfected λN-HA. Cells were frozen at -800C
for detecting protein and mRNA expression levels.
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2.5 RNAi Against miRISC Constructs in S2 Cells
1x106 S2 cells were seeded in 12 well plates and transfected with 2µg of the
appropriate dsRNA per well along with 0.05µg of the FLuc-BoxB reporter plasmid, 0.2µg
of RLuc plasmid, and 0.25µg of plasmid-expressing the λN-HA protein. All transfections
were performed using the Effectene transfection reagent. Post-transfection, the cells were
incubated for 72 hours in an incubator at 25°C to be used for luciferase assays and western
blotting. Primers for dsRNA synthesis have been listed in Table 2.1.4.
2.6 Western blotting
S2 cells were scraped in 1 ml of ice-cold 1X PBS buffer and centrifuged at 1000xg
for 10 min at 4°C. Cell pellets were resuspended in ice-cold lysis buffer and mixed
intermittently on ice for 15 minutes to ensure proper lysis. The samples were mixed in
loading buffer, boiled for 3 min at 100°C and loaded in an 8% SDS-polyacrylamide gel.
For detailed composition of the buffers and refer to table 2.1.6. The resolved proteins were
then transferred onto a PVDF membrane. A stack consisting of filter papers and sponges
soaked in transfer buffer was assembled to ensure the transfer of proteins onto PVDF
membrane. The PVDF membrane, soaked in methanol and equilibrated in transfer buffer
was placed in this stack with the resolved polyacrylamide gel. This stack was placed in the
blotting apparatus for overnight transfer at 22V.
Before incubation with antibodies, the membrane was blocked for an hour in 5%
non-fat milk in 1X TBST. The lysates were immunoblotted with primary antibodies against
FMRP (1:1000) or HA tag (1:500) for 2 hours to examine the expression of FMRP. We
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used antibodies against Β-actin for loading control. Antibodies have been listed in table
2.1.5.
To confirm the efficiency of RNAi in S2 cells, blots were probed with primary
antibodies against Dicer1 (1:1000), AGO1 (1:2000), Armitage (1:1000), AGO2 (1:1000)
and GW182 (generously gifted to us by Dr. Andrew Simmonds) (1: 2000) (Schneider et
al., 2006). The PVDF membrane was washed with 1xTBST thrice for 5 min followed by
incubation HRP-conjugated secondary antibodies. We used super signal solution to detect
the proteins on the PVDF membrane and developed the blot on an X-ray film.
2.7 Co-Immunoprecipitation
For FMRP immunoprecipitation, we seeded 4x 106 S2 cells in 25 cm2 flasks and
transfected with plasmids expressing 1 µg of EGFP-FMRP, FLAG-AGO 1, FLAG-AGO2,
and FLAG-GW182 respectively. Three days after transfection, S2 cells were harvested,
washed with ice-cold 1X PBS, centrifuged at 1000 x g for 10 min at 4°C followed by
washing with ice-cold 1X PBS buffer. Cells were re-suspended in 200µl lysis buffer,
incubated on ice for 30 minutes and centrifuged at 16000xg for 20 minutes at 40C. We
added 300 µl of the lysis buffer to the lysate and discarded the cell pellet. 50µl of the ‘Input
fraction’ was saved from the lysate for western blotting and 250 µl of the lysate was used
for FMRP-immunoprecipitation (‘IP fraction’).
The GFP-trap bead slurry (25 µl) was equilibrated as per manufacturer's
instructions and incubated with the IP fraction for about 2 hours at 40C. The beads were
washed five times with 500 µl of low and high salt wash buffer (150 mM or 300 mM NaCl)
and magnetically separated from the supernatant. The proteins bound to beads were eluted
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directly off beads with 100 µl of the 2X SDS buffer, resolved by 8% polyacrylamide gel
electrophoresis (PAGE) and probed with anti-FLAG (1:1000) and anti-EGFP antibody
(1:1000). The buffers for co-immunoprecipitation experiments have been listed in table
2.1.6.
2.8 Real-Time PCR
2.8.1 RNA Isolation and Purification
Total RNA was isolated from S2 cells transfected with 0.05µg of FLuc, 0.2µg of
RLuc, 0.25µg of λN-HA and 0.125- 0.50µg of λN-HAFMRP or untethered FMRP using
500µl of TRIzol. The RNAeasy mini kit was used to isolate and purify mRNA from cell
lysates. Briefly, the total isolated mRNA was incubated with RNase-free DNase I using
the DNA-free kit and dissolved in 50 µl of nuclease-free water. 1µg of DNA-free RNA was
used as a template for cDNA synthesis with RNA to cDNA EcoDry Premix as per
manufacturer’s instructions.
2.8.2 qRT-PCR
We used iQ SYBR Green Supermix and designed gene-specific primers for FLuc
and RLuc as described in Table 2.1.4. Melt curve analysis indicated that the primers
generated a single PCR product. Quantitative RT–PCR was performed on an iCycler
thermocycler as per the manufacturer’s instructions. For relative quantification of the
transcripts, we averaged the results from three technical replicates to generate Ct values for
each biological replicate. The Ct results were analyzed for differential fold change as
described by Livak (ΔΔCt) method (Livak and Schmittgen, 2001).
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2.9 miRNA Target-Site Prediction
Potential miRNAs targeting the SV40 3’UTR of the FLuc-BoxB reporter were
identified using the PITA algorithm. PITA scans miRNA-mRNA interactions based on the
seed sequence of the miRNA, secondary structure of the target mRNA and free energy
(Kertesz et al., 2007). For URL to the website refer to Table 2.17.
2.10 RNA Secondary Structure prediction
RNAfold web server was used to predict secondary structures of 3'UTR sequences
of known FMRP targets. The 3'UTR sequences of known FMRP target mRNAs including
Trailer-hitch, pickpocket, dRac, Chicadee, Arc1 were shown to have stem-loops very
similar in structure to the BoxB stem-loop. Predicted secondary structures are represented
in Figure 18A-B.
2.11 S2 Cell Immunofluorescence and Microscopy
2.11.1 FMRP Granules in S2 Cells:
S2 cells transfected with plasmids expressing pAc5.1B EGFP-FMRP, and deletions
for EGFP FMRP (∆RGG), FMRP(∆KH1/2), FMRP(∆KH0) were used to characterize the
phenotype of FMRP granules. Cells were transfected with 0.25µg of plasmid DNA as
described above and incubated for about 72 hours. Images were acquired using a 100x
objective (N.A.= 1.40) on an FV1000 Laser Scanning Confocal Microscope.
2.11.2 Immunofluorescence in S2 cells
S2 cells were examined for endogenous expression of FMRP and with AGO1,
GW182, or DCR1 respectively. S2 cells were allowed to adhere to a poly-d-lysine coated
dish and fixed using 4% paraformaldehyde. Cells were treated with 1 ml of
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permeabilization buffer and after incubation with blocking buffer cells were
immunostained with primary antibodies against FMRP, AGO1 and GW182 as described
previously. Images were acquired using a 100x objective (N.A. = 1.40) on a FV1000 Laser
Scanning Confocal microscope. Buffers for S2 cell immunofluorescence have been
described in Table 2.1.6.
2.11.3 S2 cell colocalization analysis
The raw images were resized using Adobe Photoshop and resolution was adjusted
to 300 pixels/inch. The images were split using the split channels feature on Fiji into green,
red and blue channels. The green channel was for FMRP, the red channel was for the
proteins of interest, and the blue channel was for DAPI. For colocalization analysis, six
independent S2 cells were measured for colocalization of FMRP with the miRISC proteins.
The images were thresholded manually before Mander's coefficient calculation using the
‘Just another colocalization plug-in’ (JaCOP) from ImageJ/Fiji (Bolte and Cordelieres,
2006). Mander's coefficient varies from 0 to 1 corresponding to overlapping images, and 1
represents 100% colocalization. The Mander's coefficient of green channel (FMRP)
colocalizing with red channel (the miRISC proteins), M2 value, was imported into Prism
for statistical analysis.
2.12 Generation, and characterization of Drosophila stocks
All stocks used in the study were raised at 250C on standard Bloomington media.
The fly stocks are listed in table 2.1.2. The Drosophila isogenized strain w1118 (or Iso31)
was used as a wild-type control. dFmr1 heterozygotes were generated by crossing flies
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from dFmr1Δ113M with flies from the w1118 genetic background. The Not1M107631, pAbpk10109
lines were balanced over CyoGFP balancer to allow for larval NMJ analysis.
Trans-heterozygotes were generated by crossing dFmr1Δ113M to all the indicated
lines and selecting against markers on the balancer chromosome. Transgenic lines with the
gawky (gw182) mutation were a kind gift from Prof. A. Simmonds (Schneider et al., 2006).
The gawky gene is located on the fourth chromosome which significantly complicates
genetic analysis. To obtain trans-heterozygous gawky mutant lines for larval NMJ analysis,
flies from w1118; pan2/P{ActGFP}unc-13GJ were crossed with flies from Tm3Sb/Ly;
gw1/ciD. F1 progeny from the cross were selected against Lyra and for GFP, Tm3Sb to
generate gw1/ActGFP.
Transgenic short-hairpin (UAS -RNAi) targeting Dcr1, Ago1, and gawky were
expressed in larvae using a specific pan-neuronal driver elav-Gal4 for larval CNS staining.
2.13 NMJ Dissections and Immunostaining
All indicated genotypes were crossed with w1118 or dFmr1Δ113M to generate
heterozygotes or trans-heterozygotes for larval NMJ analysis respectively. Wandering third
instar larvae were collected and pinned in Sylgard dishes. Larval fillets were dissected in a
calcium-free HL-3 buffer and fixed in 4% Paraformaldehyde for 15 minutes.
Fixed larvae were then rinsed in 1X PBS, permeabilized in 1XPBS-T and blocked
in the blocking solution for 1 hour. Larval filets were incubated with primary antibody
against discs large (1: 100) at 4°C overnight. Post-incubation, larvae were washed with 1X
PBS thrice for 5 minutes followed by incubation with anti-mouse Alexa Fluor 488 (1:500)
and goat Anti-HRP-Dylight-647 (1:500) for 2 hours at room temperature. Antibody against
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HRP was used to label presynaptic neuronal membranes. Post-incubation, larvae were
washed with 1X PBS thrice for 5 minutes followed by incubation with anti-mouse Alexa
Fluor 488 (1:500) and goat Anti-HRP-Dylight-647 (1:500) for 2 hours at room temperature.
Following the antibody incubation, the samples were washed extensively with 1XPBS,
mounted on a charged slide in DAPI Fluoromount G (Southern Biotech) and stored at 200C for analysis as described below. The buffer compositions for NMJ dissections and
immunostaining have been described in Table 2.1.6.
2.13.1 Image Acquisition and Quantification of NMJ
The images of NMJs were acquired at muscle 6/7 in larval abdominal segment
3(A3) using an FV1000 Laser Scanning Confocal microscope using 20X (N. A=0.85) and
60X (N. A=1.35) objectives. Max-intensity projections were obtained using the FV1000
software. All images were randomized and scored blindly to avoid potential bias in
quantification. Using cell counting plugin for ImageJ/Fiji, NMJs were manually counted
for a total number of boutons, 1b boutons, 1s boutons, branch points and tips. Based on the
size and intensity of Dlg staining, type 1b and type 1s boutons were classified. Synaptic
boutons were normalized to muscle surface area (MSA) calculated using the 20X objective.
2.14 Larval CNS Immunostaining
For immunohistochemistry, larval brains from w1118 were dissected in ice-cold 1X
PBS under 20 minutes and fixed in 4% Paraformaldehyde for 20 minutes at room
temperature. Fixed CNSes were permeabilized with 1XPBST for 20 minutes at room
temperature followed by blocking for an hour at room temperature. After blocking, the
samples were incubated with primary antibodies against FMRP (1:1000), Dicer1(1:1000),
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AGO1 (1:1000), and GW182 (1:2000) overnight at 40C. Post-incubation, larval CNSs were
washed with PBST thrice for 20 minutes and incubated in PBT with secondary antibodies
conjugated to anti mouse Alexa Fluor 488 (1:500) and anti-rabbit Alexa Fluor 568(1:500)
for two hours. Larval CNSes were then washed with PBST thrice for 10 min and mounted
on a slide using DAPI Fluoromount G (Southern Biotech). Buffer compositions for the
larval CNS immunostaining have been listed in Table 2.1.6.
Immunostained brains were imaged using a FV1000 Laser Scanning Confocal
microscope using 40X (N. A=0.90) and 100X (N. A=1.40) objectives. Maximum intensity
Z projections were assembled from 0.4 um sections using Olympus Fluoview software.
2.14.1 Larval CNS colocalization analysis
We used three independent CNSs for the analysis of protein colocalization. The
images were split into green, red and blue channels using Fiji. FMRP was imaged in green
channel, the protein of interest was imaged in the red channel and the nuclei were imaged
in the blue channel. The images were thresholded manually before the calculation of
Mander's coefficient (M1 and M2 values) using the JaCoP plugin. The M2 values for green
channel (FMRP) colocalization with red channel (miRISC/deadenylase proteins) were
imported into Prism for statistical analysis.
2.15 Larval crawling assay
Larval crawling behavior was analyzed for w1118, heterozygotes and transheterozygotes of the indicated genotypes as described previously (Kashima et al., 2017).
Average velocity and relative distance were computed from 3 independent experiments for
each genotype. Ten individual wandering third-instar larvae were rinsed briefly in 1XPBS
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and transferred from vials onto a 90 mm petri dish containing 2% agarose. The crawling
behavior was digitally recorded using iPhone 7 for 1 min in QuickTime movie (MOV)
format with time-lapse settings using the constraints described by Kashima et al. The
videos were analyzed computationally for relative crawling distance and velocity using the
LavaTrack algorithm. The URL of the website is listed in Table 2.1.7. Briefly, the position
of each larva was recorded on most frames, and the cumulative distance was computed for
four 15-second intervals. The velocity was calculated by determining the average speed
from 30 to 45 seconds as larvae were slow in first 10 seconds and some of them reached
the edge of the petri dish in last 10 seconds.
2.16 Statistical analyses
All statistical analyses including graphing was performed using ANOVA Turkey’s
one-way posthoc test or Kruskal-Wallis; Dunn’s posthoc test for the NMJ boutons. Data
are normalized to the controls and errors are presented as ± SEM with p values calculated
using GraphPad software. For larval crawling, a two-way ANOVA test was used to analyze
the data for distance and one-way ANOVA test was used to analyze average velocity.
GraphPad Prism was used to graph all data.

81

CHAPTER THREE: RESULTS
3.1 Tethered FMRP represses translation of a FLuc reporter in a dosage-dependent
manner.
To understand the role of FMRP in translation repression, we developed an in vitro
translational reporter-based assay. The experiments were based on an existing tethering
assay in Drosophila S2 cells (Pillai et al., 2004; Rehwinkel et al., 2005). We fused FMRP
with λN-HA tag that can to bind to five tandem BoxB sites cloned within the 3’UTR of the
firefly luciferase (FLuc) reporter. The λN tag is derived from the N protein of the
bacteriophage λ to enable tethering to a FLuc reporter via the BoxB structural element in
its 3’UTR (Keryer-Bibens et al., 2008) and an HA (hemagglutinin) tag for detection of the
expressed protein by Western blot. The UTR in the FLuc reporter is derived from the
Simian virus 40 (SV40) small T antigen (Figure 12A).
We transfected S2 cells with a plasmid expressing firefly luciferase (FLuc) and
Renilla luciferase (RLuc), co-transfected with and increasing concentration of plasmid
expressing λN-HA-FMRP. As a negative control, we co-transfected with a plasmid
expressing λN-HA alone. We used RLuc as a transfection control since it did not have
BoxB sites within the 3'UTR (Figure 12B). We hypothesized that tethered FMRP might
repress the translation of FLuc-BoxB reporter in a dosage-dependent manner.
We observed that λN-HA-tagged FMRP repressed the translation of FLuc reporter,
relative to λN-HA alone (Figure 12C) (p < 0.0001). At 0.125µg, 0.25µg and 0.5µg of λN82

HA tagged FMRP repressed the translation of FLuc-5xBoxB reporter was repressed by
60%, 70%, and 80% compared to controls (Figure 12C) (p < 0.0001). These results suggest
that FMRP can repress translation when tethered to the reporter mRNA in a concentrationdependent manner. We confirmed a concentration dependent increase in the levels of λNHA-tagged FMRP by Western blotting (Figure 12D).
We proposed that it was possible that FLuc protein levels in our reporter assays
could be reduced either due to a mechanism involving translational repression or mRNA
decay. To investigate whether FLuc mRNA levels decreased upon binding to FMRP, we
measured FLuc mRNA levels using qRT-PCR. We observed that FLuc mRNA levels
remained constant irrespective of the concentration of FMRP transfected in S2 cells (Figure
12E). This observation suggests that FMRP-dependent decrease in the expression of the
FLuc protein is not due to the degradation of the FLuc mRNA.
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Figure 12: Tethered FMRP represses the translation of FLuc reporter in a dosagedependent manner.
A) A schematic of λN-HA-tagged FMRP tethered to the FLuc-5xBoxB reporter in S2 cells.
λN-HA-tagged FMRP binds with high affinity to 5 tandem BoxB sites inserted into the
SV40 3’UTR of the FLuc-5xBoxB reporter. B) A schematic of the RLuc construct
(transfection control) with no BoxB sites. C) Results of S2 cells transfected with a mixture
of the FLuc-5xBoxB reporter, RLuc control, and λN-HA (empty vector) or increasing
concentrations of λN-HA-tagged FMRP (0.125µg, 0.25µg and 0.50µg). FLuc expression
was normalized to the RLuc transfection control. D) S2 cell lysates were immunoblotted
with antibodies against the HA tag and endogenous dFMRP. An antibody against Actin
served as a loading control. Arrow represents endogenous FMRP and star represents an
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isoform of approximately same size as λN-HA-FMRP. E) qPCR and luciferase activity to
quantify the expression levels of FLuc-5xBoxB reporter show consistent mRNA levels
with reduced protein expression in response to higher concentration of tagged FMRP
(****; p<0.0001). The error bars are + SEM.
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3.2 The KH domains of tethered FMRP are required for translation repression of
the FLuc-BoxB reporter.
We investigated whether domains within FMRP are required for translation
repression by tethered FMRP. We designed a series of λN-HA and EGFP tagged FMRP
deletion constructs that excluded these conserved domains: ∆RGG (470-507), ∆KH0 (116–
212) and ∆KH1/2 (226–335) (Figure 13A). Surprisingly, our results suggest that deleting
the KH1 and 2 domains significantly rescued the translation repression (p<0.0001) by
tethered FMRP (Figure 13C). We observed a 20% repression of the FLuc reporter with the
0.50µg of ∆KH1/2 FMRP plasmid (Figure 13C). Similar, albeit weaker results were
observed when the KH0 domain was deleted (Figure 13C B, 70% p<0.0001) and observed
a 50% repression of the FLuc reporter with 0.50µg of ∆KH0 FMRP plasmid (Figure 13C).
These results suggest that the KH domains of FMRP are required for mediating repression
of its target mRNAs. Since, FMRP is already tethered to the reporter via the high-affinity
λN/BoxB interaction, the requirement for these domains in translational repression appears
to be independent of their RNA binding activity.
FMRP has previously been shown to localize to cytoplasmic foci in cells that
contain mRNA (Barbee et al., 2006; Gareau et al., 2013b). Formation of these structures is
facilitated, at least in part, through the activity of FMRP’s functional domains (Gareau et
al., 2013b). We, therefore, next investigated whether deletion of the FMRP domains
required for translation repression are involved the formation of FMRP granules in the
cytoplasm. Our results suggest that deletion of the KH1 and 2 domains results in distinct
cytoplasmic puncta (Figure 13B). These structures appear to be very large and roughly
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spherical. Deletion of the RGG domains did not result in significant changes on the
morphology of FMRP granules (Figure 13B). On the other hand, deletion of KH0 domains
result in diffused localization of FMRP (Figure 13B). Since KH1 and 2 domain deletions
also rescues translation repression by FMRP, these results suggest there might be a
correlation between the size of the granules and de-repression. Taken together, we
conclude that FMRP requires the KH domains for translation repression of its target
mRNAs. This function may be associated with the morphology and dynamics of FMRP
granules.
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Figure 13: The KH domains of tethered FMRP are required for translation
repression of the FLuc-BoxB reporter and FMRP-containing granule formation.
A) A schematic representation of dFMRP showing the positions of the mRNA binding
domains in dFMRP. Deletion versions of dFMRP were cloned into EGFP and λN-HA
backbone vectors. The KH0 domains are boxed in yellow, KH1 in pink, KH2 in green,
RGG in orange, and NES in blue. B) Live S2 cells expressing EGFP, EGFP-dFMRP,
EGFP-tagged dFMRP deletion variants were imaged by confocal microscopy to detect
EGFP. All images were taken using a 100X objective. Scale bar: 20µm C) Luciferase
reporter assay for the FLuc-5xBoxB reporter with λN-HA-dFMRP and indicated λN-HAtagged deletion versions of dFMRP. S2 cells transfected with λN-HA-dFMRP (∆KH1/2)
relieve FMRP mediated repression (****; p<0.0001). The error bars are + SEM.

89

3.3 Tethered FMRP requires miRISC components to mediate repression of the
FLuc-BoxB reporter.
Previous results suggest that FMRP interact with miRNAs to regulate the
repression of target mRNAs (Edbauer et al., 2010; Jin et al., 2004b; Muddashetty et al.,
2011) . Therefore, we hypothesized that if miRNAs are involved in FMRP mediated
repression, then depleting components of the miRNA pathway should attenuate the
repression of the FLuc-BoxB reporter. Taking advantage of our translational reporter, we
sequentially knocked down Dicer-1, core miRISC components (AGO1 and GW182), by
RNAi in S2 cells and examined translation repression by tethered FMRP.
Knocking down Dicer1 (p<0.05), AGO1 (p<0.01) and GW182 (p<0.01) by
transient transfection with the FLuc and RLuc plasmids rescued FMRP-mediated
translation of the FLuc-BoxB reporter (Figure 14A). As a control, the introduction of
dsRNA targeting EGFP had no significant impact on reporter expression (Figure 14A). We
confirmed the knockdown efficiency of RNAi constructs targeting Dicer1, AGO1, and
GW182 in transfected cells using antibodies and detected expression of these proteins by
Western blotting (Figure 14B-D). Taken together, our data suggest that tethered FMRP
requires the components of the miRNA pathway to repress translation of the FLuc-BoxB
reporter.

90

Figure 14: Tethered FMRP requires miRISC components to mediate repression of
the FLuc-BoxB reporter.
A) S2 cells were transfected with the FLuc-5xBoxB reporter, RLuc, vectors expressing
λN-HA or λN-HA-tagged FMRP and co-transfected with dsRNA targeting Dicer1, AGO1,
or GW182. We used RNAi against EGFP as our negative control, which did not affect the
expression levels of FLuc reporter. RNAi against Dicer1 and candidate miRISC
components (AGO1, GW182) significantly attenuated FMRP mediated repression. Data is
shown from three independent experiments (*; p<0.05, **; p<0.01). The error bars are +
SEM. B-D) We used Western blotting to visualize the efficiency of Dicer1, AGO1, and
GW182 RNAi knockdown using antibodies specific to the indicated proteins. Actin was
used as a loading control. All target protein levels were significantly reduced.
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3.4 FMRP interacts biochemically with AGO1 and GW182 in S2 cells.
Our results suggest that FMRP requires AGO1, GW182, and Dicer1 to repress
translation of the reporter. Next, we investigated the nature of this interaction using coimmunoprecipitation assays in S2 cell lysates. We co-transfected S2 cells with FLAGtagged AGO1 or GW182 and EGFP-tagged FMRP and isolated binding partners of FMRP
using GFP-Trap (Figure 15A). We found that FMRP pulled down both AGO1 and GW182
under low salt conditions (150mM NaCl) (Figure 15B). The pull-down of GW182 was not
nearly as efficient as that of AGO1. We propose that this could be due to an indirect
interaction between FMRP and GW182, which is directly mediated by AGO1. To test this
possibility, we co-transfected with an additional construct expressing HA-tagged AGO1 in
order to alter the stoichiometry of the FMRP: AGO1 complex. Surprisingly, this had no
impact on the amount of GW182 that was pulled down with FMRP (Figure 15B). It is
possible that this is due to the abundance of target mRNAs for the miRISC components or
the kinetics of the interaction of FMRP with AGO1.
In contrast, immunoprecipitation under high salt conditions (300mM NaCl)
completely abolished the interaction between FMRP and GW182 (Figure 15C). However,
interactions between FMRP and AGO1 were unperturbed. In these experiments, AGO2
was used as a positive control, as previous studies have shown a strong biochemical
interaction between FMRP and both AGO1 and AGO2 (Caudy et al., 2002) (Figure 15C).
Together, our data support the conclusion that FMRP interacts in a complex with the
miRISC components, AGO1 and GW182. Moreover, these results also suggest an indirect
relationship between FMRP and GW182 mediated either by AGO1 or some other protein.
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Figure 15: FMRP co-immunoprecipitates with AGO1 and GW182 in S2 cells.
A) GFP-trap beads were used to pull-down EGFP-tagged FMRP and EGFP protein from
S2 cell extracts. The proteins were resolved by SDS-PAGE and probed with antibodies
against GFP and FMRP. Endogenous FMRP was detected in both non-transfected cells and
cells transfected with EGFP-FMRP. EGFP-FMRP was detected in the IP fraction of
transfected cells. B) Lysates from S2 cells transfected with plasmids expressing FLAGtagged AGO1, GW182 were co-immunoprecipitated using GFP-trap under low salt
conditions (150mM NaCl) C) Lysates from S2 cells transfected with plasmids expressing
FLAG-tagged AGO1, GW182 were co-immunoprecipitated using GFP-trap under high salt
conditions (300mM NaCl). FLAG-AGO2 was used as a positive control.
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3.5 Untethered FMRP can repress the translation of the FLuc-BoxB reporter.
Previous studies suggest that FMRP is capable of recognizing and binding to small
stable stem loops that are similar in structure to BoxB motifs and regulate the translation
of specific target mRNAs (Bechara et al., 2009; Zalfa et al., 2003). Thus, we next asked
whether transfected FMRP lacking the λN-HA tag was also able to repress the translation
of the FLuc-5xBoxB reporter in a dosage-dependent manner.
To test this hypothesis, we modified the FLuc-BoxB reporter and reduced the
number of BoxB motifs or remove them altogether (Figure 16A). We generated a series of
FLuc-BoxB reporter with 3x, 1x, and 0x copies (essentially the “wild-type” SV40 3’UTR)
of the BoxB sequence. Surprisingly, we found that FMRP was capable of repressing the
translation of the FLuc reporter containing only a single BoxB stem-loop just as well as
the reporter containing five BoxB stem-loops (Figure 16C; p<0.0001) and as well as
tethered FMRP. In contrast, translation of a reporter containing no copies of the BoxB
sequence was unaffected by untagged FMRP (Figure 16C). These results suggest that
mRNAs with small stem-loops could be targets for FMRP, expanding the toolbox for the
study of the mechanism of FMRP-mediated translation repression.
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Figure 16: Untethered FMRP can repress the translation of FLuc-BoxB reporter.
A) A schematic representation of FLuc-1xBoxB reporter showing a single BoxB site and
a binding site for miR-958. B) A schematic representation of FLuc-0xBoxB reporter with
no stem loops for FMRP to bind. C) Results for luciferase reporter assay for FLuc-5xBoxB,
FLuc-3xBoxB, FLuc-1xBoxB and FLuc-0xBoxB reporter with 0.125µg, 0.25µg, and 0.50
µg of FMRP. (**; p<0.01, ****; p<0.0001). The error bars are + SEM.
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3.6 miRNA-958 requires FMRP to mediate translation repression of the FLuc-BoxB
reporter.
Our data provide evidence for a requirement of the miRISC complex for FMRPmediated translation repression. However, it was unclear whether this process required
miRNA binding to the target mRNA in order to repress its translation. In order to identify
miRNAs that bind to the FLuc reporter, we ran the SV40 3’UTR (with the BoxB sequence)
through a miRNA prediction algorithm, PITA, which scans for miRNA-mRNA base pair
interactions and predicts a score for the interaction (Kertesz et al., 2007; Peterson et al.,
2014). The prediction is based on the seed sequence of the miRNA, secondary structure of
the target mRNA, and free energy of the interaction. miR-958 was predicted to have the
highest score for FLuc mRNA interaction (Figure 17B). Moreover, the putative binding
site for miR-958 is only 80 nucleotides from the BoxB stem-loop sequence, which is just
outside the “footprint” of the RISC complex when it interacts with a target mRNA.
Therefore, we transfected S2 cells with a plasmid expressing miR-958 to determine if it
can repress translation of the minimal FLuc-1xBoxB reporter.
We found that transfected miR-958 represses translation of the FLuc mRNA by
34% compared to control (Figure 17A p<0.01). To elucidate the nature of the interaction
between FMRP and miR-958, we used RNAi to knock down endogenous FMRP
expression and asked if it disrupted miR-958-mediated repression of the FLuc-1xBoxB
reporter. We found that miR-958 was unable to repress the translation of the FLuc reporter
in the absence of FMRP in S2 cells (Figure 17A). This suggests that FMRP and the miR958 are both required for effective translation repression of target FLuc mRNA.
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To further validate the requirement of FMRP, we used the FLuc-0xBoxB reporter
lacking the BoxB stem-loop sequences (Figure 16B). This reporter is not repressed by
untagged FMRP (Figure 16C). We found that miR-958 did not repress the translation of
the FLuc-0xBoxB reporter even in the presence of endogenous FMRP (Figure 17A). This
suggests that miR-958 mediated translation repression requires FMRP’s interaction with
the target mRNA via the BoxB sequence. These results suggest that FMRP binding is
required for miR-958 to mediate translation repression. Moreover, these findings suggest
that FMRP and miRNAs can function cooperatively in the repression of a shared target
mRNA. However, miR-958 is expressed in S2 cells at extremely low abundance (Figure
17B). Therefore, we rule out endogenous miR-958 in repressing the translation of the
FLuc-1xBoxB reporter in the tethered FMRP experiments described above.
Next, we sought to determine the identity of actual miRNA that might work in
concert with FMRP to repress translation of the FLuc-BoxB reporter. We used PITA to
identify other endogenous, abundant miRNAs in S2 cells that a predicted to bind to the
3'UTR of the FLuc-BoxB reporter. In our analysis, bantam, miR-33, miR-13, miR-2a, and
miR-2b were predicted to bind to the FLuc-BoxB 3’UTR (Figure 17B). We have cloned
the indicated miRNAs in the miRNA-expression plasmid for future analysis.
To validate an interaction between FMRP and the identified miRNAs, we pulled
down FMRP-containing RNPs from S2 cells expressing EGFP-tagged FMRP using a GFP
trap system. The isolated mRNA and miRNA levels from FMRP-IP fraction were analyzed
by quantitative real-time PCR (qRT-PCR). Compared to non-transfected control cells, we
observed an enrichment of bantam, miR-2b, miR-13b and miR-33 in cells expressing
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tagged FMRP (Figure 17C). We also observed non-specific binding using the IgG
antibody. Future experiments are needed to optimize the RNA-IP experiment to explore
the coordinated nature of FMRP and miRNA in target mRNA repression.
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Figure 17: miRNA-958 requires FMRP to mediate translation repression of the FLucBox reporter.
A) Cells were co-transfected with the FLuc-1xBoxB reporter, RLuc and a plasmid
expressing miR-958. Interestingly, miR-958 was unable to repress the reporter when
FMRP was depleted by RNAi. Furthermore, in the absence of BoxB motifs, miR-958 could
not repress the FLuc reporter. These results suggest a requirement of FMRP (or FMRP
binding) for miR-958 to mediate the repression of FLuc-BoxB reporter. Values in columns
represent the % of the control activity (*; p<0.05, **; p<0.01). The error bars are + SEM.
B) List of miRNAs predicted by PITA algorithm for binding to SV40 3’UTR in the FLuc
reporter based on the position relative to the first nucleotide in the 3’UTR sequence, seed
region, free energy of binding and reads per million C) FMRP containing mRNPs were
pulled down and the isolated mRNAs were analyzed by the quantitative real-time PCR
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(qRT-PCR) using probes against miRNAs. Bantam, miR-2b, miR-13b and miR-33 were
enriched in FMRP associated RNP fraction vs non-transfected controls. The results are
from a single experiment (therefore, no error bars are shown).
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3.7 FMRP can repress the translation of FLuc reporters for known target mRNAs
that contain BoxB-like sequences in their 3’ UTRs.
Since FMRP represses the translation of a reporter mRNA containing the BoxB
motifs, we hypothesized that FMRP may be interacting with endogenous target mRNAs
via similar sequences. Previous studies suggest that FMRP directly interacts with mRNAs
encoding for the degenerin/sodium channel family protein, Ppk, GTPase activating protein,
dRac1, microtubule associated protein Futsch, actin binding protein Chic, activityregulated cytoskeletal protein, Arc1, protein involved in mRNA localization, Tral, and
itself , dFmr1 (Dictenberg et al., 2008; Lee, 2003; Monzo et al., 2006; Reeve et al., 2005;
Schaeffer et al., 2001; Xu et al., 2004; Zhang et al., 2001).
We used RNAfold to analyze the secondary structure of the 3’UTRs of the indicated
mRNAs and observed stem loop sequences similar in structure to BoxB motifs (Figure
18A). First, we determined if these mRNAs co-immunoprecipitated with FMRP in S2 cell
lysates (Figure 18C). We found that dRac, dFmr1 and chic mRNAs were enriched in
FMRP associated mRNP complexes. ppk is not expressed in S2 cells. These results suggest
a direct association of FMRP with the indicated mRNA targets. Next, we determined
whether untagged FMRP could repress the translation of FLuc-3’UTR reporter for all these
candidate mRNAs. In each reporter, we removed the SV40 3’UTR sequence including the
BoxB sequences and replaced with the 3’UTR of the above-mentioned genes. We observed
that untagged FMRP effectively replaced translation of FLuc-ppk 3’UTR, FLuc-chic
3’UTR and FLuc-Arc1 3’UTR in a dosage dependent manner (Figure 18D-E, p < 0.0001).
However, FMRP did not repress the translation of the FLuc-dRac1 3’UTR or FLuc-Tral
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3’UTR. (Figure 18E). These results suggest that FMRP mediated repression may not be
limited to the BoxB-like stem-loop structures.
We also determined the 3’UTRs of the candidate genes for the most well
characterized FMRP-binding motif, G-quartets using QGRS mapper (Kikin et al., 2006).
In our analysis, we found the 3’UTR of dRac with 2 and Arc1 with 6 predicted G-quartets
while ppk, chic and Tral had none. Therefore, the analysis suggests that structural motifs
may not be enough for FMRP to mediate repression and repression may be sequence
specific. FMRP is predicted to bind to ACUK or WGGA sequence in the target mRNA for
repression. It would be interesting to determine whether the repression is being mediated
by the stem loops or specific sequences such as WGGA or ACUK).
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Figure 18: Untethered FMRP can repress the translation of FLuc reporters for
known target mRNAs that contain BoxB-like sequences in their 3’ UTRs.
A) The secondary structure of the FLuc-1xBoxB structure was folded by RNAfold
software. Stable structures were colored by base-pairing probabilities (ranging from red to
green). Box B motifs denoted in red color were predicted to be stable structure. B) The
3’UTR of ppk contained Box-B like motifs as predicted by RNAfold. C) FMRP containing
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RNPs were pulled down from S2 cells and analyzed for associated mRNAs by Reversetranscription (RT-PCR). Chic, dRac and dFmr1 were enriched in FMRP-IP fraction
compared to the IgG control. Ppk is not expressed in S2 cells. D) The entire 3’UTR region
of ppk, chic and tral was cloned downstream of FLuc reporter. The SV40-3’UTR of the
FLuc reporter was swapped by the entire 3’UTR of the indicated genes. These reporters
were co-transfected with the RLuc, λN-HA (control), and with increasing concentration of
untethered FMRP (0.125µg, 0.25µg and 0.50µg). Luciferase data shown here for the FLucppk 3’UTR (****; p < 0.0001). The errors are in + SEM. E) S2 cells were co-transfected
with the FLuc-ppk 3’UTR, FLuc-chic 3’UTR, FLuc-tral 3’UTR reporters, RLuc, λN-HA
(control) and 0.50µg of FMRP. Columns indicate the % of the control activity (****; p <
0.0001). The errors are in + SEM.
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3.8 FMRP colocalizes to granules containing AGO1 and GW182 in S2 cells.
Previous studies have demonstrated that FMRP localizes to P-bodies and stress
granules along with translationally repressed mRNAs, miRNAs, AGO1, GW182 and
several other RBPs, to mediate gene silencing (Parker and Sheth, 2007). The formation of
these cytoplasmic granules is linked to the miRNA-mediated repression pathway (Eulalio
et al., 2007c). Therefore, we wanted to determine if FMRP colocalizes with Dicer1, AGO1,
and GW182 in cytoplasmic RNP granules in S2 cells.
We performed immunostaining in S2 cells for FMRP, Dicer1, AGO1, and GW182
(Figure 19A). Our results show a strong colocalization of FMRP with AGO1 (Mander’s
coefficient 0.7+ 0.02) and GW182 (0.9+ 0.01) in S2 cells (Figure 19B). These results
suggest that dFMRP and miRISC proteins are in close proximity in the cell and potentially
interact with each other. On the other hand, we did not observe substantial colocalization
of FMRP with Dicer1 (0.45+0.02) (Figure 19B). Interestingly, we observed a distinct
perinuclear distribution of Dicer1 (Figure 19A). This distinct phenotype for Dicer1 has not
been shown in other systems. This observation needs to be explored in future experiments
to determine if this is significant for its function as a microRNA processor.
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Figure 19: FMRP colocalizes to granules containing AGO1 and GW182 in S2 cells.
A) S2 cells were stained with antibodies against FMRP, Dicer1, AGO1, and GW182.
Images for FMRP (green), Dicer, AGO1 and GW182 (red) were taken at 100X objective.
Cell nuclei were counterstained with DAPI (blue). Arrows point towards the regions with
an overlap of green and red fluorescent signals. Scale bar: 5µm B) Degree of colocalization
(Mander’s coefficient) was calculated for the overlap between green and red channels. N=6
independent S2 cells were analyzed for the analysis. (****; p < 0.0001). The error bars are
mean + SEM.
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3.9 FMRP is expressed in the same population of neurons as AGO1 and GW182
within the cell bodies in the Drosophila larval CNS.
Our data in S2 cells suggest FMRP to colocalize in granules with the miRISC
components. Next, we wanted to determine if FMRP also colocalizes with the miRISC
components in vivo. Previous studies suggest that FMRP can localize to neuronal transport
granules in mammalian and Drosophila neurons (Cougot et al., 2008). These granules are
enriched in translationally repressed mRNAs, along with several miRNAs, miRISC
components and various RBPs. Moreover, dendritic P-bodies have also been suggested to
contain FMRP, miRNAs, miRISC components with translationally repressed mRNAs
(Cougot et al., 2008). The assembly of all the proteins involved in mRNA regulation in
distinct granules is speculated to modulate translation in neurons (Barbee et al., 2006).
Given the role of FMRP and miRNAs in translation regulation for proper neuronal
morphology, we hypothesized FMRP would colocalize with the miRISC components and
Dicer1 in neurons within the Drosophila larval CNS.
Ventral ganglia of the Drosophila CNS contains descending motor neurons that
project into the muscles carrying information to control flight, walking and other motor
functions (Strausfeld, 2009). Therefore, we counterstained ventral ganglia to examine the
intracellular localization of FMRP with Dicer1 and the miRISC components (Figure 20A).
To examine the subcellular localization of FMRP and miRISC components in more detail,
we imaged neuronal cell bodies of motor neurons along the midline (Figure 20B). We
observed a strong overlap of pixels between FMRP, AGO1 (0.6+0.02) and GW182
(0.8+0.01) within the soma of the cell bodies (Figure 20C). However, we do not have the
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required resolution to determine if FMRP colocalizes with AGO1 and GW182.within
neuronal granules in motor neurons. This question will require further analysis.
In our analysis, FMRP did not show a as strong of an overlap with Dicer1 (0.5+0.05,
Figure 20C). However, Dicer1 showed the similar perinuclear phenotype within cell bodies
of the ventral ganglia as seen earlier in S2 cells (Figure 20B). Again, since there are no
published studies to indicate that Dicer1 localizes to nuclear membranes, this could be a
novel and potentially interesting finding.

108

Figure 20: FMRP is expressed with AGO1 and GW182 in the same population of
motor neurons within the Drosophila larval CNS.
A) Ventral ganglion of the wandering third instar larvae stained with antibodies for FMRP
(green), Dicer1, AGO1, and GW182 (all red). The panels are from a single optical section
as acquired by confocal microscopy. The arrows in the merged panels indicate the overlap
of FMRP fluorescent intensities between FMRP (green) and the indicated components of
the miRNA pathway Scale bar: 50µM. B) Cell bodies within the ventral ganglion were
imaged using 100X for FMRP (green) and the indicated miRISC components (red). Cell
nuclei are counterstained for DAPI. The arrows in the merged panels indicate the overlap
of FMRP fluorescent intensities between FMRP (green) and the indicated components of
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the miRNA pathway (red). C) Degree of colocalization (Mander’s coefficient) was
calculated for the overlap between green and red channels. N=3 independent CNS images
were analyzed for the analysis. (****; p < 0.0001). The error bars are the mean + SEM.
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3.10 dFmr1 interacts with GW182 to regulate synaptic growth.
We used Drosophila larval NMJs as our model system to further characterize the
phenotypic significance of the interaction between FMRP and miRISC components. The
Drosophila larval NMJ is a well-defined and relatively simple model system to identify
genetic interactions between genes by assessing the changes in synaptic structure and
function (Budnik, 1996). It has been shown that FMRP interacts genetically with AGO1 to
control NMJ growth (Jin et al., 2004b). Flies singly heterozygous for dAGO1 (ago1k00208/+)
and dFmr1 (dFmr1∆113/+) have normal NMJ phenotype and a similar number of boutons
compared to wild-type larvae. However, removal of a one copy of AGO1 in a
phenotypically normal FMRP heterozygous background (an FMRP; AGO1 transheterozygote) results in a highly significant overgrowth of the NMJ similar to that seen in
a dFmr1 homozygous null mutant (Jin et al., 2004b). These results suggest that FMRP
requires AGO1 to regulate proper synaptic development. Based on the published studies
and our results in S2 cells, we speculated that FMRP might also genetically interact with
GW182 to regulate NMJ development.
To test the hypothesis, we examined whether dAGO1 (as a positive control) and
gawky (fly GW182) could modulate the synaptic growth regulated by dFmr1 using the loss
of function dFmr1 mutants (dFmr1∆113). We assessed the morphology of NMJs at muscle
6/7 in abdominal segment 3 of wandering third instar larva (Figure 21A). We stained
dissected NMJs with pre-synaptic marker anti-HRP and post-synaptic marker anti Dlg for
characterizing synaptic morphology. First, we examined the NMJs from dFmr1
heterozygotes

(dFmr1∆113/+),

AGO1

heterozygotes
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(ago1k00208/+)

and

gawky

heterozygotes (gw1/+). In our hands, dFmr1∆113 nulls did not survive to the third instar
stage (data not shown). Counting the number of synaptic boutons for each of these
genotypes assessed changes in NMJ development. We normalized the total number of
boutons to the corresponding muscle surface area (MSA) to avoid any biases that might
arise as the result of variations in the muscle size among different larvae (Figure 21B).
We did not observe any significant increase in the number of synaptic boutons for
AGO1 or dFmr1 heterozygotes relative to controls (Figure 21B). The gawky heterozygotes
showed a small but significant increase in the number of boutons compared to w1118
controls (25% increase, p < 0.05 Figure 21B). These results suggested that either loss of a
single copy of gawky was sufficient to cause synaptic defects or could also stem from the
combined effects of the balancer in the gawky heterozygous background.
To address if AGO1 or GW182 act in the same pathway as FMRP, we generated
trans-heterozygotes for dAGO1 (ago1k00208/+; dFmr1∆113/+) and GW182 (gw1/+;
dFmr1∆113/+), respectively. Previous results have shown that dFmr1 causes synaptic
overgrowth at the NMJ while dFmr1 heterozygotes appear to have normal NMJ (Jin et al.,
2004b). These results suggest that a single copy of FMRP can regulate proper synaptic
development at the NMJ. If both the genes interact with dFmr1 in the same pathway, then
reducing expression levels of these genes in dFmr1 heterozygous background should
disrupt the function of FMRP and cause synaptic overgrowth.
We observed a robust increase in boutons for gawky trans-heterozygotes compared
to dFmr1 heterozygotes (80% increase, p<0.0005). The phenotype was stronger than
gawky heterozygotes suggesting that the observed phenotype was due to the disruption of
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gawky at the NMJ (Figure 21A-B). Taken together, the results suggest that FMRP interacts
with GW182 in the same pathway to regulate synaptic growth. However, contrary to
published results, the NMJs from AGO1 trans-heterozygotes background did not show any
significant changes in the number of boutons (Figure 21A-B). It is possible that the allele
for AGO1 used in our studies might have picked up a unique set of mutations or interactions
with suppressors may have disrupted its function.
Based on the size, shape glutamatergic type I boutons are classified into 1b (big)
and 1s (small) boutons that are derived from two different motor neurons (Hoang and
Chiba, 2001). We quantified the number of 1b and 1s boutons at the larval NMJ for the
indicated genotypes (Figure 22A-B). The gawky trans-heterozygotes showed an even more
pronounced change in the number of 1b boutons compared to mutant dFmr1 heterozygotes
(75% increase, p<0.0005) (Figure 22A). Moreover, unlike 1b boutons, we did not observe
any significant changes in the number of 1s boutons for AGO1 or gawky transheterozygotes (Figure 22B). AGO1 heterozygotes did not show any significant changes in
the number of 1b or 1s boutons at the NMJ (Figure 22A-B).
dFmr1 nulls are also characterized by extensive neuronal branching at the NMJ
(Zhang et al., 2001). Therefore, we quantified NMJs on the extent of synaptic branching
and the number of branch-tips for the AGO1 and gawky trans-heterozygotes (Figure 22CD). We observed no significant changes in the number of branch points or tips in our
analysis. Taken together, our results indicate that FMRP requires GW182 to the proper
synaptic structure during development at the Drosophila NMJ.
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Figure 21: dFmr1 interacts genetically with gawky to regulate synaptic growth.
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for AGO1, gawky
and trans-heterozygotes for AGO1, gawky (generated in the dFmr1∆113 background) were
analyzed for NMJ phenotype. The size of the NMJ (normalized to muscle surface area or
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MSA) was determined at muscle 6/7 in abdominal segment A3 for each genotype as
indicated. The NMJs were stained against postsynaptic density marker Dlg (green). Scale
bar: 50 µM. B) The total number of synaptic boutons/MSA were quantified for each
genotype. Trans-heterozygotes of gawky had a robust increase in the number of boutons
/MSA (normalized to control) compared to dFmr1∆113 heterozygotes. (*p< 0.05, **p <
0.01; ****; p < 0.0001). The error bars are the mean + SEM.
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Figure 22: Trans-heterozygotes of gawky display an increased number of 1b boutons.
NMJs for the indicated genotypes were quantified for various parameters of NMJ
morphology and compared to dFmr1 heterozygotes. A) Total number of 1b boutons/MSA
were significantly higher for gawky trans-heterozygotes. B) No significant difference was
observed for the normalized 1s boutons. C) No significant difference was observed for the
tips for the indicated genotypes. D) Branch-points were not affected in the indicated
genotypes. (*p< 0.05, **p < 0.01; ****; p < 0.0001). The error bars are the mean + SEM.
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3.11 dFmr1 and miRNA pathway components do not interact to control rates of larval
locomotion.
It was recently showed that an overgrowth of synaptic boutons at the larval NMJ
correlates with locomotion dysfunction in dFmr1 heterozygotes (Kashima et al., 2017).
Using a quantitative larval locomotion algorithm, known as “Larvatrack’’, the authors used
dFmr1 heterozygotes (dFmr1∆50/+, and dFmr13/+) and found that synaptic overgrowth
correlated with augmented crawling velocity. Taking a cue from their observations, we
used Larvatrack to investigate if dFmr1 heterozygotes (dFmr1∆113/+) used in our NMJ
analysis, exhibits increased velocity (Figure23 A-B). Based on our NMJ analysis, we
speculated that in comparison to dFmr1 heterozygotes, we would observe a higher velocity
for gawky heterozygotes and gawky trans-heterozygote larvae and no changes for AGO1
heterozygotes or AGO1 trans-heterozygote larva.
Although we did not observe synaptic overgrowth with dFmr1∆113 heterozygotes in
our NMJ analysis, dFmr1 heterozygote larvae moved 30% faster than w1118 controls (Figure
23B). These results suggest that changes in locomotion dysfunction does not correlate
directly with changes in the number of synaptic boutons. Similar to the results observed in
dFmr1 heterozygotes, we found that gawky heterozygotes were 22% faster than w1118
controls while AGO1 heterozygotes were 12% faster than the controls. However, neither
AGO1 nor gawky trans-heterozygotes displayed any significant alterations in velocity in
comparison to the dFmr1 heterozygotes (Figure 23B). Contrary to previously reported
observations our results suggest that there is no significant correlation between the
observed synaptic overgrowth and aberrant velocity in Drosophila larva. It is also possible
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that beyond a certain threshold, larvae cannot move faster, which could explain the lack of
any significant changes in the velocity between and dFmr1 heterozygotes or transheterozygotes for the miRISC components
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Figure 23: dFmr1 and miRNA pathway components do not interact to control rates
of larval locomotion.
Larval locomotion was quantified using the “LarvaTrack” algorithm for indicated
genotypes. A) Cumulative distance traveled in millimeters by the larvae over 60 seconds
was plotted for comparison between w1118, dFmr1 heterozygotes, AGO1, gawky
heterozygotes and for the trans-heterozygotes for AGO1 and gawky. No significant
differences were observed between the trans-heterozygotes of the indicated genotypes and
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dFmr1 heterozygotes. B) Quantitative histogram showing the velocity of the larvae for the
indicated genotypes. No significant difference was observed between the indicated
genotypes and the dFmr1 heterozygotes. The error bars are the mean + SEM.
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3.12 The role of dFmr1 in regulating synaptic growth is independent of the
deadenylase complex (CCR4 and NOT1), PABP or the decapping complex (Dcp1).
We sought to determine the downstream mechanisms by which FMRP-GW182
regulates synaptic morphology. Previous studies suggest that GW182 can act as the
mediators of translation repression by interacting with the components of deadenylase
machinery, including CCR4 and NOT1 and PABP to mediate deadenylation-dependent
and independent mode of translation repression (Braun et al., 2013). Moreover, GW182
also interacts with the decapping enzyme, Dcp1 to mediate gene silencing via the miRNAs
(Rehwinkel et al., 2005). GW182 assembles with CCR4, NOT1, PABP, and Dcp1 into
mRNP granules along with several miRNAs and associated mRNA targets in P-bodies
(Decker and Parker, 2012). Therefore, we hypothesized that FMRP might interact with
CCR4, NOT1 or PABP downstream of GW182 to mediate translation repression, which
might play a role in proper synaptic development at the larval NMJ.
3.13 FMRP is expressed with CCR4, CAF1, and NOT1 within the same cells in the
larval CNS.
We immunostained larval ventral ganglia to investigate if FMRP and the
deadenylase components co-localized to the same population of cells. In flies, CCR4 and
NOT1 are the main enzymes responsible for the deadenylation of target mRNAs (Temme
et al., 2004). CAF1 (fly ortholog of POP2) associates with CCR4 and possesses catalytic
deadenylation ability (Temme et al., 2010). CAF1 can replace CCR4 as the main catalytic
component of the deadenylase complex and the two proteins may exhibit some functional
redundancy. We observed a diffused localization of FMRP and CCR4 in the CNSs (Figure
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24A). Compared to CCR4, NOT1 and CAF1 appeared to be more punctate in appearance
(Figure 24A). In our analysis, there was strong overlap between FMRP and CCR4
(0.65+0.01) followed by NOT1 (0.6+0.01) and CAF1(0.5+0.01). However, we do not have
sufficient optical resolution to conclude if FMRP colocalizes with deadenylase components
at the larval NMJ. Imaging at higher resolution is required to determine the extent of
colocalization between FMRP and the deadenylase components in granules.
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Figure 24: FMRP is expressed with CCR4, CAF1, and NOT1 within the same cells
in the larval CNS.
A) Ventral ganglion of the wandering third instar larvae stained with antibodies targeting
FMRP (green), CCR4, NOT1, and CAF1 (red). The panels are from a single optical section
as acquired by confocal microscopy. The arrows in the merged panels indicate the overlap
of FMRP fluorescent intensities between FMRP (green) and the indicated deadenylase
components. Scale bar: 50µM. Cell bodies within the ventral ganglion were imaged using
100X for FMRP (green) and the indicated deadenylase components (red). The arrows in
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the merged panels indicate the overlap of FMRP fluorescent intensities between FMRP
(green), CCR4, NOT1, and CAF1(red). C) Degree of colocalization (Mander’s coefficient)
was calculated for the overlap between green and red channels. N=3 independent CNSs
were analyzed for the analysis (****; p < 0.0001). The error bars are the mean + SEM.
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3.14 FMRP shows no genetic interaction with CCR4, NOT1, PABP or Dcp1 at the
larval NMJ.
Next, we used the larval NMJ as our in vivo model system to validate the
interactions between FMRP and CCR4, NOT1, PABP or Dcp1. Based on the known
interactions of GW182 in vitro, we hypothesized that CCR4, NOT1, PABP or Dcp1 may
act downstream of FMRP and GW182 in the same genetic pathway to regulate synaptic
development. To test this possibility, we asked if CCR4, NOT1, PABP or Dcp1 would
show trans-heterozygous interactions with FMRP at the larval NMJ. We examined the
NMJs from dFmr1 heterozygotes (dFmr1∆113/+), and heterozygotes for the candidate
genes: TwinGS12209/+, Not1M107631/+, pAbpk10109 /+, and Dcp1442p/+. We assessed the
changes at NMJ by counting the total number of synaptic boutons for each of these
genotypes. Again, as the number of synaptic boutons can increase proportionally with
MSA, we normalized synaptic bouton numbers against MSA for quantification. We did
not observe any significant increase in the number of synaptic boutons for the heterozygous
larvae of Twin, Not1, PABP or Dcp1 (Figure 26, 27). We observed a 5% increase in Twin
Heterozygotes, increase, 0% increase in Not1 heterozygotes, 10% increase in pAbp
heterozygotes and a 5% decrease in Dcp1 heterozygotes.
Next, we removed a single copy of the Twin, Not1, pAbp, and Dcp1 in the dFmr1
heterozygous mutant background to generate trans-heterozygotes for the indicated genes.
As described previously, an increase in the number of synaptic boutons in transheterozygotes for these genes compared to controls would suggest genetic interactions
within the FMRP pathway. In comparison to dFmr1 heterozygotes, Twin trans125

heterozygotes (TwinGS12209/+; dFmr1∆113/+) displayed a 10% increase in synaptic boutons.
Not1 trans-heterozygotes (Not1M107631/+; dFmr1∆113/+) exhibited a 15% increase over
dFmr1 heterozygotes (Figure 26B). The trans-heterozygotes for pAbp (pAbpk10109 /+;
dFmr1∆113/+) showed a 5% increase, and Dcp1 (Dcp1442p/+; dFmr1∆113/+) displayed a 5%
decrease in the number of synaptic boutons over dFmr1 heterozygotes (Figure 27B). None
of these results were statistically significant. These results suggest FMRP does not interact
with CCR4, NOT1, PABP or DCP1 in the same pathway to controlling NMJ growth. It is
possible that FMRP may regulate NMJ development via the miRISC through a nondeadenylation dependent mechanism. Another possibility for the lack of any observed
phenotype at the NMJ could be due to the redundancy between deadenylase enzymes and
PABP in Drosophila. It would be interesting to test the genetic interactions between FMRP
and CAF1 and other subunits of the NOT1 enzyme complex.
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Figure 25: dFmr1 shows no genetic interactions with Twin or Not1 at the larval NMJ.
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for Twin, Not1 and
trans-heterozygotes for Twin, Not1 (generated in the dFmr1∆113 background) were analyzed
for NMJ phenotype. The size of the NMJ was determined at muscle 6/7 in abdominal
segment A3 for each genotype as indicated. The NMJs were stained against postsynaptic
density marker Dlg (green). Scale bar: 50 µM. B) Total number of synaptic boutons/MSA
were quantified for each genotype. No significant difference was observed for the transheterozygotes of Twin and Not1 in the number of boutons/MSA (normalized to control)
compared to dFmr1∆113 heterozygotes. The error bars are mean + SEM.
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Figure 26: dFmr1 shows no genetic interactions with pAbp or Dcp1 at the larval
NMJ.
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for pAbp or Dcp1,
and trans-heterozygotes for pAbp or Dcp1 (generated in the dFmr1∆113 background) were
analyzed for NMJ phenotype. The size of the NMJ was determined at muscle 6/7 in
abdominal segment A3 for each genotype as indicated. The NMJs were stained against
postsynaptic density marker Dlg (green). Scale bar: 50 µM. B) Total number of synaptic
boutons/MSA were quantified for pAbp and Dcp1. No significant differences were
observed between the indicated trans-heterozygotes and dFmr1∆113 heterozygotes. The
errors bars are mean + SEM.
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3.15 FMRP does not interact with CCR4, NOT1, PABP or Dcp1 to control rates of
larval locomotion.
We used the larval crawling assay as a rapid and quantitative approach to screen
components of the deadenylase complex including Twin (the fly ortholog of CCR4) and
the scaffold protein Not1 as well as pAbp and the decapping enhancer Dcp1 for defects in
locomotion. Based on the studies by Kashima et al. we speculated that trans-heterozygotes
for these candidate genes might display a faster velocity than controls and might correlate
with the synaptic overgrowth phenotype (Kashima et al., 2017).
First, we examined the crawling velocity of the wild-type (w1118) and dFmr1
heterozygote (dFmr1∆113p/+) larvae using “LarvaTrack” algorithm. We observed dFmr1
heterozygotes to be 30% faster than the wild-type larvae (p< 0.01) (Figure 25). dFmr1
heterozygotes display a normal NMJ phenotype, therefore, these results do not suggest a
correlation between larval locomotion and synaptic overgrowth. Compared to wild-type
larvae, Not1 heterozygotes (Not1M107631/+) displayed a higher velocity (p<0.01). However,
heterozygotes of twin (TwinGS12209/+), pAbp (pAbpk10109 /+), or Dcp1 (Dcp1442p/+) did not
exhibit a higher velocity than the wild-type larvae. These results suggest that compared to
wild type larvae, Not1 heterozygotes are significantly more hyperactive than the Twin,
pAbp, or Dcp1 heterozygous larvae (Figure 25).
Next, we compared the locomotion between the dFmr1 heterozygous control larvae
and animals that were trans-heterozygotes for the indicated genes. As with miRNA
pathway components, none of the trans-heterozygotes displayed any significant increase in
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velocity in comparison to the single heterozygotes genotypes (Figure 25). Together, our
results do not support locomotion to be a functional readout for NMJ defects.
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Figure 27: dFmr1 does not interact with Twin, Not1, pAbp or Dcp1 to control rates of
larval locomotion.
Larval locomotion was quantified using “LarvaTrack” algorithm for the indicated
genotypes. Average velocity for the larvae was plotted for comparison between w1118 and
dFmr1 heterozygotes and the trans-heterozygotes for the indicated genotypes. No
significant difference was observed between the indicated genotypes and the dFmr1
heterozygote controls in the rate of velocity. The error bars are mean + SEM.
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CHAPTER FOUR: DISCUSSION
4.1 FMRP requires AGO1 and GW182 to mediate translation repression.
Previous studies suggest that FMRP associates with essential components of the
miRNA pathway such as Dicer and AGO proteins, as well as with specific miRNAs
(Cheever and Ceman, 2009; Edbauer et al., 2010; Jin et al., 2004b). FMRP associated miR125b and miR-132 have opposite effects on dendritic spine morphology in hippocampal
neurons (Edbauer et al., 2010). Muddashetty et al. suggest that FMRP promotes the
formation of an Ago2-miR-125a complex on PSD-95 mRNA and this translation inhibitory
complex is regulated by the phosphorylation of FMRP. However, the mechanism by which
the association of FMRP regulates translation via the miRNA pathway is not fully
understood. Using an in vitro translation reporter assay in S2 cells, we provide the first
evidence of a requirement for the downstream effector GW182 in FMRP mediated
repression. We speculate that the interaction of FMRP with AGO1 and GW182 may
facilitate miRNAs to bind to target mRNAs and repress their translation.
The GW182 proteins are important miRISC effectors, and are recruited by AGO
proteins to miRNA-targeted mRNAs (Fabian et al., 2012). FMRP could either interact
directly with GW182 or interact with GW182 in an AGO-dependent manner. Our results
suggest a weak interaction between FMRP and GW182 in co-IP assays, which could
suggest an AGO-dependent interaction at play. However, we do not rule out the possibility

134

of our assay conditions playing a role in our observations. Additional experiments are
required to further clarify the nature of these biochemical interactions.
Why might FMRP interact with GW182? GW182 binds to AGO proteins and act
as a platform to recruit several proteins to the target mRNAs for gene silencing (Fabian
and Sonenberg, 2012). Some studies suggest that GW182 can bind to PABP and thus
interfere with mRNA circularization for target mRNA repression (Fabian and Sonenberg,
2012). However, other studies in cell culture assays suggest that GW182 recruits CCR4NOT1 to mediate deadenylation independent or deadenylation dependent mode of
translation repression (Fabian and Sonenberg, 2012). We speculate that FMRP could bind
to multiple RBPs through GW182 to form an mRNP complex for translation regulation. A
growing number of studies suggest that miRNAs and RISC components localize in Pbodies, stress granules and neuronal granules (Buchan, 2014). Moreover, GW182 can act
as a scaffold for P-body assembly as their depletion can cause dissolution of P-bodies
(Eulalio et al., 2007a). Based on these observations, it is likely that FMRP through its
interaction with GW182 could reside simultaneously in different types of mRNP granules,
each regulating translation of specific targets in different ways.
4.2 FMRP requires AGO1 and GW182 to control NMJ development.
Previous studies by Jin et al. suggest genetic interactions between FMRP and
AGO1 is crucial to regulate larval NMJ phenotypes (Jin et al., 2004b). We investigated
genetic interactions between FMRP and both AGO1 and GW182 using Drosophila larval
NMJs as our model system. We provide evidence for the first time that FMRP requires
GW182 to regulate NMJ development. We observed a robust phenotype of synaptic
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overgrowth at the larval NMJ for GW182 trans-heterozygotes. However, we could not
detect any effect on the NMJs with AGO1 trans-heterozygotes. We speculate that either
the AGO1 allele picked up suppressor mutations that may have disrupted its function.
Nevertheless, our results suggest that FMRP requires components of miRNA pathway to
control NMJ development. These interactions are crucial to control synaptic plasticity.
How might the interaction control NMJ phenotype? One possibility may be that the
interaction between FMRP and miRISC components may be involved in the transport and
repression of specific transcripts within neuronal granules in motoneuron axons and that
control NMJ development. Thus, disruption of the interaction between FMRP and miRISC
components may be linked to defects in mRNP assembly or mRNA transport at the NMJ.
However, future experiments are needed to explore the hypothesis in detail.
We also investigated downstream components that might regulate NMJ
development. However, none of the trans-heterozygotes for the candidate genes (Twin,
Not1, pAbp or Dcp1) tested displayed a synaptic overgrowth phenotype. It may be possible
that an alternate pathway might compensate for the function of Twin, Not1, PABP or Dcp1
at the NMJ to control the NMJ phenotype. Therefore, the components by which FMRP
through GW182 may regulate the NMJ phenotype still remains unclear. Future
experiments will need to identify the downstream components of FMRP and GW182
involved in mediating translation control within the same pathway.
4.3 Cooperative interaction between FMRP and miRNAs regulate translation.
Our results strongly suggest that FMRP binds to the BoxB stem loop sequence in
the 3’UTR of the FLuc reporter, which is in close proximity to the binding site for miR136

958. Both miR-958 and FMRP can cooperatively repress the translation of the FLuc
reporter. Interestingly, depletion of FMRP from S2 cells resulted in attenuation of miR958-mediated repression. These results suggest that FMRP may play a role in recruiting
miRNAs to nearby binding sites in target mRNAs. A similar cooperative regulation was
reported for the PSD-95 mRNA by the association between FMRP and miR-125a for
proper synaptic morphology and function (Muddashetty et al., 2011).
We have identified putative miRNAs that might work in coordination with FMRP
to repress translation of the FLuc-BoxB reporter. However, future experiments are required
to verify the actual miRNAs involved in FMRP mediated repression in our assay. An
obvious question is how might FMRP load miRNAs to the target mRNA? FMRP does not
have a canonical miRNA-binding domain for interaction with miRNAs directly. Therefore,
we speculate that either FMRP can interact with miRNAs via Dicer1 or through its
interactions with AGO1 or GW182. To test this possibility, future experiments will be
needed to gain mechanistic insights into this process.
4.4 Role of the KH domains in FMRP mediated translation repression.
Our results demonstrate that the KH domains of FMRP are involved in FMRP
mediated translation repression (Figure 13B). We examined the effects of deleting RNA
binding domains from FMRP on the translation of FLuc reporter and found that ∆KH1/2
FMRP rescued the translation repression activity of tethered FMRP. Why might KH
domains be involved in mediating this process? The KH domains of FMRP have been
suggested to facilitate the direct assembly of miRNAs on some target mRNAs in vitro
(Plante et al., 2006)). The authors suggested that FMRP could act as an acceptor of mature
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miRNAs derived from Dicer processing of pre-miRNAs. Therefore, FMRP through its KH
domains may cooperate with Dicer1 in miRNA assembly on target mRNAs for repression.
It is possible that in our assays, deleting KH domains from FMRP comprised the ability of
FMRP to form miRNA complex on target mRNAs. Additional experiments will be
required to determine if KH domains are involved in direct interaction with Dicer1 for
miRNA assembly on the FLuc-BoxB reporter.
Another possibility by which KH domains can regulate FMRP mediated translation
repression is through its ability to enhance the interaction between mRNA and miRNAs.
KH domains of FMRP are known to enhance the formation of the kissing complex in vitro,
where a target mRNA is bound to miRNAs in a specific secondary structure conformation
(Bassell and Warren, 2008). While we have not directly investigated the secondary
structure of the 3’ UTR of the FLuc mRNA when bound to FMRP, it is possible that FMRP
mediates interaction between FLuc mRNA and miRNAs through its KH domain. This
interaction may alter secondary structure and orient the FLuc mRNA in a favorable
conformation for miRNA interaction. Further experiments are required to directly
investigate this hypothesis.
A recent study suggests that FMRP can interact directly with ribosomes through its
KH domains and the steric conflicts between KH domains and P-site tRNA can cause
ribosomal stalling leading to translation repression (Chen et al., 2014). These results
suggest a miRNA independent mode of translation repression for FMRP. Since ribosomes
are stalled in the CDS region of target mRNAs, we do not consider ribosomal stalling as a
potential mechanism for FMRP mediated repression for tethered experiments with the
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FLuc-BoxB reporter. However, it is possible that the secondary structure of the mRNA
may allow for FMRP (bound at the 3'UTR) to interact with ribosomes within the CDS. So,
this mechanism cannot be ruled out completely for endogenous target mRNAs.
4.5 Role of the KH domains in FMRP granule formation.
A recent study by Gareau et al. suggest that FMRP granules assemble via its KH0
domains (Gareau et al., 2013b). KH0 domains are involved in self-interaction of FMRP
and may potentially direct multiple protein-protein interactions in RNP granules (Gareau
et al., 2013b). KH0 domain of FMRP plays an important role in FMRP’s interaction with
FXR1/2, CYFIP1 and FMRP interacting protein (FIP) (Hu et al., 2015). Moreover, lack of
a GxxG motif in KH0 provides it the flexibility to interact with multiple mRNAs, including
the ncRNA, BC1 (Hu et al., 2015). In consistent with the studies by Gareau et al. using live
cell imaging, we observed that deleting KH0 domains from FMRP results in diffused
localization of smaller FMRP granules in cells. These results suggest that FMRP requires
the KH0 domain for granule assembly. Based on these studies, we speculate that FMRP
through its KH0 domains may sequester translationally repressed mRNAs, miRNAs, and
core miRISC components to granules. An increased local concentration of miRNAs and
miRISC proteins may facilitate efficient translation repression of target mRNA. The
observed dissociation of granules due to deletion of the KH0 domain might be due to the
removal of the interactions between FMRP, target mRNA, miRISC components and other
RBPs. Further, FRAP studies suggest that FMRP requires KH0 domains to shuttle from
cytosol to granules. In an absence of shuttling activity, FMRP may not bind to specific
proteins for granule formation and translation regulation. It would be interesting to
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characterize how the KH0 domain chaperones transcripts and associated proteins to
granules from free cytosolic fraction. Another explanation for the diffused localization of
the KH0 deleted FMRP protein might be non-specific binding of this mutated FMRP to
other proteins in absence of KH0 domain. KH0 domain is required for FMRP to form
dimers. Therefore, an absence of self-dimerization of FMRP may lead to non-specific
binding with other proteins, leading to loss of function phenotypes.
In contrast to Gareau et al., we observed that ∆KH1/2-FMRP induced the formation
of bigger FMRP granules in S2 cells. A possible explanation for the observed aberrant
granules may be a loss of translation regulation by FMRP. Previous studies suggest that
∆KH1/2-FMRP has compromised RNA and protein shuttling activity between the granule
and the cytosol (Gareau et al., 2013b). Therefore, we speculate that ∆KH1/2-FMRP may
be trapped with miRNAs or miRISC components in granules. It would be interesting to
characterize whether aberrant granule formation contributes to FXS pathology.
Unpublished data from Barbee lab suggests that disease-causing KH1 and two point
mutants induce the formation of aberrant granules similar in morphology to ∆KH1/2FMRP. Further experiments are needed to investigate if difference in size and dynamics
are due to mRNAs and miRISC proteins being trapped in these granules.
4.6 RBPs can promote miRISC targeting at the 3’UTR of target mRNA.
Sequences or structures in the 3'UTR of specific mRNAs may influence FMRP's
role in the microRNA-mediated translation repression pathway. miRNAs mediate
translation repression mainly by binding to seed regions within the 3'UTR. Various other
RBPs can also interact with 3'UTRs in a sequence-specific manner. In both cases, this
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interaction is necessary to modulate gene expression. An interplay between RBPs and
miRNAs in the 3'UTR can either induce a structural switch in the mRNA which could
facilitate miRISC assembly on the target mRNA. Conversely, RBP interaction with the
3’UTR could occlude miRNAs from binding to their target mRNAs.
As an example of RBP-mediated modulation of miRNA pathway, the 3'UTR of the
p27 mRNA is regulated by miR-221, miR-222, and Pumilio (Kenny and Ceman, 2016).
Pumilio is a ubiquitously expressed sequence-specific RBP. However, binding site for
these miRNAs in the 3’UTR of p27 mRNA are inaccessible to miRISC for binding,
because they are found within regions of complex secondary structure. There is evidence
that Pumilio1 interacts with p27-3'UTR and induces a local change in mRNA structure. As
a consequence of this structural change, the seed sequence is exposed, which allows for the
interaction of miRISC components with the target mRNA. Another example of RBPmediated miRISC modulation is the role of dead end 1 (Dnd1) protein in inhibiting miRNA
binding to target mRNAs. Dnd1 has been shown to compete with miRNAs to inhibit
miRNAs from associating with their target sites (Kedde et al., 2007).
Other RBPs have been demonstrated to have both an agonizing or antagonizing
function in miRNA-mediated translation regulation. For example, the polypyrimidine tract
binding protein (PTB) and human antigen R (HuR) can suppress or enhance miRNA
binding in the 3'UTR of a subset of target mRNAs (Kenny and Ceman, 2016; Kim et al.).
Therefore, we speculate that FMRP may serve a similar function in promoting miRNA
binding to the 3’UTRs of some target mRNAs. FMRP may facilitate or inhibit miRNA
mediated repression by modification of secondary structure in target mRNA, either by
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making miRNA binding site accessible, or by masking miRNA binding sites. The factors
that modulate secondary structure in the target mRNA require further investigation.
4.7 Future directions
Our data suggests that FMRP interacts with the components of the miRNA pathway
to mediate translation repression. Based on our data, we propose a model where FMRP
binds to 3’UTRs of target mRNAs and recruits the miRISC to a nearby miRNA binding
site for translation repression (Figure 28). It would be interesting to perform a CLIP-Seq
for FMRP to identify its mRNA targets in neuronal cell lines or in motor neurons and
investigate whether these targets are co-regulated by miRNAs and FMRP.

Future

experiments will also be required to identify other RBPs that may interact with FMRP and
miRNAs for coupled control of mRNA translation in neurons.
Our results also suggest a role of KH domains in FMRP translation in a mRNA
independent way. It would be interesting to generate stable cell lines for ∆KH FMRP, pull
down associated RBPs with FMRP, and compare these RBPs with the cell lines expressing
wild-type FMRP to identify KH domain mediated FMRP-RBP interactions. The
experiments will help identify if the absence of KH domains can lead to non-specific
interactions of FMRP with other RBPs which leads to aberrant granules. Further, FMRP
lacking KH domains and RGG domain should be investigated for their interactions with
components of the miRNA pathway. We could also track the movement of miRISC
components or other RBPs in FMRP granules in motor neurons using super-resolution
microscopy to measure the dynamics of their interactions within FMRP granules.
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Taken together, that work described in this thesis (and experiments that will
logically follow) could help shed some light on the mechanisms by which FMRP regulates
translation of target mRNAs with miRNAs, as well as identify key neuronal transcripts
whose translation is affected by the loss of FMRP. An understanding of these processes
will help in the development of therapeutic approaches to find a cure for FXS.
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Figure 28: Proposed model of how FMRP interacts with the miRNA pathway to
regulate translation.
We propose that FMRP first recognizes structural elements in target mRNA and then
recruits the miRISC components to mediate translation repression. FMRP potentially
interacts with the miRISC complex through AGO1 which then recruits GW182 to mediate
repression. GW182 could potentially interact with the components of the deadenylase
complex (CCR4, NOT1) to mediate either deadenylation dependent or an independent
mode of degradation. GW182 could also interact with other RBPs to mediate RNA
trafficking to P bodies.
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APPENDIX: LIST OF ABBREVIATIONS
1. AGO protein - Argonaute protein
2. APP - Amyloid Precursor Protein
3. ApppN - An unmethylated cap analog
4. ARC- Activity-regulated cytoskeleton- associated protein
5. BC1 - Brain Cytoplasmic RNA1
6. CaMKII - Calcium/Calmodulin-Dependent Protein Kinase II
7. CDS - Coding Sequence
8. CYFIP1- Cytoplasmic FMRP Interacting Protein
9. Dlg- Discs large
10. Dnd1- Dead end 1
11. 4E-BP- eIF4E-binding proteins
12. FMRP - Fragile X mental retardation protein
13. FXPOI- Fragile X-related primary ovarian insufficiency
14. FXTAS - Fragile X tremor ataxia syndrome
15. GW - Glycine-Tryptophan
16. HITS-CLIP - High-throughput sequencing of RNA isolated by crosslinking
immunoprecipitation
17. HRP-Horseradish peroxidase
18. HuR- Human antigen R
19. IRES - Internal Ribosome entry site
20. KH domains - Ribonucleoprotein K homology domains
21. LCD - Low complexity domain
22. MNK - MAP kinase-interacting serine/threonine- protein
23. mGluR 5 - Metabotropic glutamate receptor 5
24. MAP1B - Microtubule associated protein
25. NES - Nuclear export signal
26. NLS - Nuclear localization signal
27. MSA-Muscle surface area
28. NR2A- N-methyl-D- aspartate receptor subunit
29. NXF - Nuclear export factor
30. PABP - Poly-A binding protein
31. PACT- Protein activator of the interferon induced protein kinase
32. PAIP2 - Polyadenylate-binding protein-interacting protein 2
33. P-bodies - Processing bodies
34. PSD 95 - Post synaptic protein 95
35. Rac1- Ras-related C3 botulinum toxin substrate 1
36. RBP - RNA binding protein
37. RBD- RNA binding domain
38. RGG box - Arginine Glycine Glycine box
39. RISC - RNA induced silencing complex
40. RNP - Ribonucleoprotein complex
41. SIX3- Sine oculis homeobox homolog transcription factor
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42. SMN-Survival of motor neuron
43. Sod1 - Superoxide Dismutase
44. SoSLIP - Sod1 mRNA Stem Loops Interacting with FMRP
45. TNRC - Trinucleotide repeat-containing protein
46. TRAP- Translating Ribosome Affinity Purification
47. TRBP- TAR RNA binding protein
48. UTR - Untranslated Region
49. ZC3H14-Zinc-finger CysCysCysHis [CCCH]-type 14
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